1. Introduction
Cancer remains a prominent global health challenge, with 2022 surveillance data from the International Agency for Research on Cancer (IARC) revealing 20 million incident cases (including non-melanoma skin cancers) and 9.7 million cancer-attributed deaths [1]. The lifetime cancer risk approaches 20%, with gender-specific mortality rates of 11.1% in males and 8.3% in females. Lung carcinoma leads in global incidence (2.5 million cases, 12.4%), followed sequentially by breast (11.6%), colorectal (9.6%), prostate (7.3%), and gastric malignancies (4.9%). Gender-specific analysis identifies breast and lung cancers as principal determinants of female and male oncologic morbidity/mortality, respectively [1,2]. Notably, sustained mortality reductions in developed nations (e.g., 2.3% annual decline in the US) reflect enhanced early detection protocols and precision oncology innovations in targeted therapies and immunomodulation [3].
Modern oncology employs multimodal therapeutic strategies, including surgical resection, radiation therapy, systemic chemotherapy, molecularly targeted agents, immune checkpoint inhibitors, endocrine therapies, and investigational approaches [4,5]. Despite its systemic efficacy, conventional chemotherapy faces substantial clinical limitations due to dose-limiting toxicities and acquired resistance mechanisms, representing a persistent therapeutic challenge in cancer management. Tumors constitute complex ecosystems comprising transformed cells, stromal components, and remodeled extracellular matrices. The tumor microenvironment (TME) orchestrates critical oncogenic processes through dynamic interactions between malignant cells and resident stromal populations, including tumor-associated macrophages, cancer-associated fibroblasts, endothelial cells, and pericytes. These interactions drive tumor initiation, progression, and metastatic dissemination through paracrine signaling and extracellular matrix remodeling [6]. Chemoresistance emerges through multifactorial mechanisms, including drug metabolism alterations, target modification, efflux transporter upregulation, enhanced DNA repair capacity, and apoptotic pathway dysregulation [4]. Recent evidence highlights the context-dependent nature of resistance mechanisms, which are influenced by the cellular phenotype, tumor evolution dynamics, and cumulative mutational load [5].
Natural products exert multimodal anticancer effects through the simultaneous modulation of molecular targets and oncogenic pathways, including apoptosis regulation, proliferation inhibition, migration suppression, angiogenesis blockade, and metastatic prevention. These bioactive compounds initiate intracellular signaling cascades culminating in cancer cell death, offering promising therapeutic potential against drug-resistant malignancies [7]. While terrestrial sources have historically dominated in anticancer drug discovery, marine ecosystems provide unparalleled chemical diversity due to their unique ecological pressures and evolutionary adaptations [8,9].
Marine-derived bioactive compounds exhibit multi-target anticancer efficacy through cross-pathway modulation. Accumulated evidence confirms that the NF-κB, mTOR, and PI3K/Akt pathways constitute primary therapeutic targets of marine-origin antitumor agents [10]. Emerging pharmacological insights further reveal the coordinated regulation of tumorigenic processes through MAPK cascades, Wnt/β-catenin signaling, and their intricate network crosstalk. The MAPK superfamily, encompassing the ERK, JNK, and p38 subfamilies, serves as a master regulator of cellular homeostasis, governing proliferation, differentiation, and apoptotic machinery [11]. In the canonical ERK pathway, Ras GTPase activation initiates membrane recruitment of RAF kinases, which phosphorylate MEK1/2 to subsequently activate ERK1/2 via dual phosphorylation at conserved Thr/Tyr motifs (T202/Y204 in ERK1; T183/Y185 in ERK2). Phosphorylated ERK1/2 dimers translocate to the nucleus, where they mediate transcriptional activation through the kinase-dependent modification of effector proteins (Elk-1, c-Myc, CREB), thereby promoting cell cycle progression (via cyclin D1 induction), apoptosis resistance (through Bad inactivation), and metastatic potential [12]. p38 MAPK signaling, a stress-responsive hub, requires MKK3/6-mediated phosphorylation at T180/Y182 for activation. Nuclear-localized p38 orchestrates inflammatory responses (TNF-α/IL-1β production), cell cycle arrest (p21-dependent), and mitochondrial apoptosis (Bax/Bak activation) via the phosphorylation of transcription factors (ATF2, MEF2C) and chromatin remodelers (MSK1/2). Contemporary studies highlight its non-canonical roles in post-transcriptional regulation through RNA-binding protein phosphorylation (e.g., HuR-mediated mRNA stabilization), autophagosome biogenesis, and stress granule assembly [13]. JNK signaling (c-Jun N-terminal kinase), an evolutionarily conserved stress-activated pathway, demonstrates synergistic interactions with the NF-κB and JAK/STAT networks to balance survival–autophagy–apoptosis triage. Mechanistically, JNK activation induces cytoprotective autophagy through Bcl-2 phosphorylation, representing an adaptive mechanism against chemotherapy-induced apoptosis [14]. The canonical Wnt/β-catenin axis, frequently targeted by marine compounds, requires specific ligand–receptor engagement (e.g., Wnt3a/10b) with Frizzled receptors and LRP5/6 co-receptors [15]. This interaction inhibits β-catenin degradation, allowing nuclear accumulation and TCF/LEF-dependent transcription of oncogenic targets—a process validated in multiple marine compound studies addressing epithelial-derived malignancies [15,16].
Marine ecosystems, encompassing microbial communities (e.g., bacteria, fungi), macroalgae, seagrasses, and diverse fauna (including corals, ascidians, and crustaceans), have been established as treasure troves of structurally unique secondary metabolites. These compounds exhibit potent cytotoxicity against a broad spectrum of cancer cell lines, positioning marine-derived bioactive agents as innovative chemical scaffolds for therapeutic development and pivotal resources for next-generation anticancer drug discovery [17,18]. The clinical validation of marine-derived pharmaceuticals is underscored by 17 FDA/EMA-approved agents as of 2022 [19]. Notably, four structurally distinct marine-inspired compounds—lurbinectedin, polatuzumab vedotin, enfortumab vedotin, and belantamab mafodotin—have recently gained regulatory approval for treating ovarian cancer, diffuse large B-cell lymphoma, urothelial carcinoma, and multiple myeloma, respectively [18]. Furthermore, cytarabine (Cytosar-U®) represents a paradigm-shifting achievement. This sponge-derived nucleoside analog selectively targets S-phase progression through DNA polymerase inhibition, demonstrating efficacy against acute leukemias and meningeal malignancies. Similarly, ziconotide (Prialt®), a Conus magus venom peptide, revolutionized pain management through selective N-type calcium channel blockade, providing an opioid alternative for refractory cancer- and AIDS-related pain [20]. Contemporary marine drug discovery continues to yield structurally novel leads, exemplified by the tubulin-binding polyketides PM050489 and PM060184 currently in clinical development [21,22,23]. Among marine-derived producers, fungal secondary metabolites have emerged as a prolific source of anticancer scaffolds, with Penicillium spp. contributing 22% of characterized marine fungal natural products. This genus represents a chemically diverse reservoir of structurally unique compounds with novel mechanisms of action, underscoring its significance in marine natural product research [24,25,26,27].
The marine-derived didemnin family has emerged as a novel anticancer pharmacophore with multi-target therapeutic potential, demonstrating synergistic antitumor mechanisms through molecular-level interventions. Current research confirms their ability to (1) disrupt ribosomal function to suppress global protein biosynthesis, (2) concurrently activate mitochondrial-mediated and death receptor-mediated apoptosis pathways, (3) induce cell cycle checkpoint dysregulation in malignant proliferation, (4) remodel tumor microenvironment immunogenicity, and (5) exhibit inhibitory effects against viral-associated oncogenesis [28]. Comparative pharmacological evaluations revealed that didemnin B demonstrates superior cytotoxic activity, which facilitated its progression to clinical trials. However, phase II studies identified dose-limiting toxicities including neuromuscular impairment and hepatotoxicity, prompting structural optimization efforts [29]. The semi-synthetic derivative plitidepsin (Aplidin®), featuring a dehydrodidemnin B scaffold, exemplifies successful structure–activity relationship optimization. Xenograft models demonstrate an enhanced therapeutic index compared to the parental compound through improved pharmacokinetic profiles and reduced off-target distribution [30]. Clinical validation comes from the NAPOLY-1 trial, where plitidepsin achieved a 20.7% overall response rate in relapsed/refractory multiple myeloma, with manageable hematological toxicity [30]. Notably, combination regimens demonstrate translational potential. Synergistic effects were observed when didemnin B was combined with sorafenib in lymphoma models [31]. A phase Ib trial (NCT02371135) demonstrated a 60% disease control rate in patients with T-cell lymphoma receiving plitidepsin–gemcitabine–carboplatin regimen without overlapping toxicity profiles [31,32].
2. Secondary Metabolites of Marine-Derived Penicillium spp.
The seminal discovery of penicillin from Penicillium spp. by Alexander Fleming in 1928 marked the dawn of modern mycology-based drug discovery. Over the past three decades (1991–2023), marine-derived Penicillium strains have emerged as prolific producers of structurally diverse secondary metabolites with significant pharmacological potential. Extensive investigations have characterized their unique biosynthetic pathways, while mechanistic studies have elucidated structure–activity relationships underlying their anti-inflammatory and anticancer properties [33,34,35,36,37,38]. Marine ecosystems harbor phylogenetically diverse Penicillium spp. with exceptional ecological plasticity, rendering this ascomycete genus a strategic resource for cytotoxic lead discovery. Systematic bioprospecting spanning 1991–2017 yielded more than 200 cytotoxic metabolites with antitumor potential from marine-derived Penicillium spp. [33,39]. This comprehensive review systematically evaluates cytotoxic and antitumor secondary metabolites from marine-derived Penicillium spp. reported between 2018 and 2024, encompassing 177 characterized compounds with 93 structural novelties (52.5% discovery rate). The identified metabolites are classified according to their biosynthetic origins, with particular emphasis on their molecular mechanisms of action and structure–activity relationship (SAR) profiles. In this paper, the cytotoxicity of related compounds was evaluated by the IC50 value to assess its strength, and the specific efficacy levels were potent (<1 μM or <0.5 μg/mL), notable (1–10 μM or 0.5–5 μg/mL), moderate (10–30 μM or 5–15 μg/mL), mild (30–50 μM or 15–25 μg/mL), and negligible (>50 μM or >25 μg/mL) [33].
Penicillium spp. have emerged as prolific producers of bioactive secondary metabolites, with Penicillium citrinum (22, 12.3%), Penicillium chrysogenum (19, 10.6%), Penicillium granulatum (8, 4.5%), and Penicillium polonicum (7, 3.9%) constituting the major sources of anticancer compounds, collectively accounting for 31.3% of the characterized molecules. Additional significant contributors include Penicillium sclerotiorum (6, 3.4%), Penicillium brasilianum (5, 2.8%), and Penicillium citreonigrum (5, 2.8%), while 31 other species each yield 0.6–2.2% of metabolites, including Penicillium copticola, Penicillium parvum, and Penicillium thomii (4, 2.2% each). Notably, 24.6% of compounds are derived from unidentified Penicillium strains (Figure 1). Recent investigations of cytotoxic compounds derived from marine Penicillium spp. have revealed remarkable chemical diversity, with approximately 52.5% being newly identified metabolites. The annual statistics presented in Figure 2 demonstrate this sustained discovery trend, detailing both cumulative bioactive compounds and novel cytotoxic agents identified through annual screening, thereby establishing marine Penicillium as a continuously valuable resource for drug discovery research [40,41,42].
As prolific producers of bioactive secondary metabolites, marine-derived Penicillium spp. demonstrate ubiquitous colonization across pelagic ecosystems, inhabiting marine sediments, sea water, and epibiotic substrates. This ecological versatility correlates with exceptional biosynthetic plasticity through niche-specific adaptation, manifested as specialized metabolic arrays fulfilling distinct ecological functions. In this review, a statistical analysis of marine Penicillium spp. habitats revealed distinct ecological preferences: Marine sediments (32.8%), characterized by high organic content and microbial diversity, served as the predominant source. Symbiotic associations with marine faunas (20.9%) provided specialized ecological niches, while marine floras (15.8%), particularly algae and seagrasses, offered nutrient-rich substrates. Pelagic environments contributed 18.6% of isolates, with mangroves (6.2%) representing unique terrestrial–marine interfaces supporting fungal growth through complex ecological interactions. Notably, 5.6% of isolates originated from atypical environments (wastewater, sand, soil), demonstrating the genus’s remarkable ecological plasticity and adaptive capacity across diverse habitats (Figure 3).
Marine-sourced Penicillium spp. exhibit extraordinary chemodiversity through their biosynthetic repertoire, generating structurally distinct specialized metabolites spanning alkaloids, polyketides, terpenes, steroids, and other types. The 177 characterized compounds predominantly comprise polyketides (98, 55.4%), followed by alkaloids (42, 23.7%), terpenoids (24, 13.6%), and steroids (13, 7.3%) (Figure 4). Structural diversity analysis identified 23 distinct subclasses: polyketides encompass 12 subfamilies (Figure 5), including azaphilones, chromones, xanthones, and quinones; alkaloids are represented by 7 structural classes, such as indole derivatives and pyrrolizidines; terpenoids consist of 2 subgroups (sesquiterpenoids, meroterpenoids and diterpenoids); and steroids.
3. Chemical Diversity of Marine-Derived Penicillium Secondary Metabolites
3.1. Polyketides
Polyketides, biosynthesized through the polyketide synthase (PKS)-mediated sequential condensation of carboxylic acid precursors, represent the most structurally diverse class of fungal secondary metabolites. These compounds exhibit remarkable chemical variability and broad-spectrum bioactivities, accounting for 55.4% of cytotoxic compounds identified from marine-derived Penicillium spp. This predominance underscores their significance in marine natural product-based drug discovery [43,44]. The structural diversity of anticancer polyketides derived from marine Penicillium spp. is shown in Figure 6 and Figure 7.
3.1.1. Azaphilones/Azaphilonoids
Azaphilones (or azaphilonoids) represent a structurally diverse class of fungal polyketide-derived molecules, characterized by a highly oxygenated pyranoquinone bicyclic core. To date, 13 distinct structural subtypes have been characterized within this class of compounds [45]. Recent investigations of marine-derived Penicillium sclerotiorum E23Y-1A yielded a novel compound with a dioxolane-based framework, penidioxolane C (1), which demonstrated selective cytotoxicity against five human tumor models—chronic myelogenous leukemia (K562), hepatocarcinoma (BEL-7402/HepG2), gastric adenocarcinoma (SGC-7901), non-small-cell lung carcinoma (A549), and cervical carcinoma (HeLa)—with IC50 values ranging from 23.94 to 60.66 µM [46].
The marine alga-associated Penicillium sclerotiorum KM265451.1 yielded two novel azaphilones—8a-epi-hypocrellone A (2) and 8a-epi-eupenicilazaphilone C (3)—alongside known analogs 4 and 5. Compound 2 demonstrated selective neuroblastoma cytotoxicity against SH-SY5Y cells with an IC50 value of 35.6 µM. A comparative SAR analysis of 2–5 revealed α-H (R1) and β-hydroxyl (R2) substituents as critical determinants for target selectivity, suggesting that spatial orientation influences bioactivity [47].
Bromophilones A (6) and B (7), representing the first reported azafluorones featuring a methylene-bridged phenyl-pyranoquinone scaffold, were isolated from Penicillium canescens associated with the Mediterranean sponge Agelas oroides. Stereochemical configuration significantly influenced bioactivity, with 7 demonstrating notable cytotoxicity against L5178Y murine lymphoma (IC50, 8.9 µM) and A2780 human ovarian carcinoma (IC50, 2.7 µM) cells, while its stereoisomer 6 exhibited markedly reduced potency [48].
3.1.2. Benzopyranoid Derivatives
Marine-derived benzopyranoids exhibit unparalleled structural diversity in their pharmacophoric architectures, highlighting their potential as privileged scaffolds for pharmaceutical innovation. The analysis of marine fungal isolates (2000–2023) reveals that 33.9% of characterized benzopyran derivatives exhibit antitumor potential, underscoring their privileged scaffold status in drug discovery [49]. The starfish-sourced Penicillium sp. GGF16-1-2 was found to produce carbon-bridged dicitrinone G (8). This architecturally distinct dimer demonstrated moderate cytotoxicity against pancreatic adenocarcinoma cell lines BXPC-3 and PANC-1, with IC50 values of 12.25 and 24.33 μM, respectively. Notably, it exhibited 1.5- to 2.0-fold enhanced potency compared to doxorubicin hydrochloride (18.24 μM for BXPC-3 and 24.00 μM for PANC-1). Furthermore, a mechanistic study suggested that compound 8 may promote apoptosis in BXPC-3 cells by influencing the activation of CASP3 [50]. Concurrently, a chemical investigation of sponge-associated Penicillium citrinum SCSIO41017 yielded citrinin derivatives 9–12, with the tetracyclic meroterpenoid 12 demonstrating marked antineoplastic activity against estrogen receptor-positive breast adenocarcinoma MCF-7 cells, with an IC50 value of 1.3 µM. Congeners 9–11 exhibited pancancer inhibitory activities across a panel of tumor cell lines, including SF-268, MCF-7, HepG-2, and A549, with IC50 values spanning from 13.0 to 115.3 µM [51]. In addition, compound 12 exhibited negligible cytotoxic activity, with an IC50 value of 49.15 µM against A549 cells [52].
3.1.3. Chromones
Marine-derived Penicillium citrinum BCRC09F458 yielded chromone derivatives 13–16, with structure–activity profiling revealing critical pharmacophoric determinants. Epiremisporine B (16) bearing a 2-hydroxyl moiety demonstrated dual cytotoxicity against A549 (IC50, 32.29 µM) and HT-29 cells (IC50, 50.88 µM), exhibiting enhanced potency over non-hydroxylated analogs 13–15. The 2’β-methoxy-substituted epiremisporine E (15, IC50, 43.82 µM) showed greater activity against A549 cells than α‘-methoxy congeners 13 and 14 (>100 µM). Mechanistic analysis confirmed mitochondrial transmembrane potential collapse and caspase-3 activation in 15/16-treated A549 cells. The SAR study established hydroxylation at C-2 and β-stereospecific methoxylation at C-2’ as critical enhancers of apoptogenic efficacy in marine chromones [52]. Epiremisporines F–H (17–19) isolated from Penicillium citrinum BCRC09F458 exhibited dose-dependent cytotoxicity against the HT-29 (IC50, 21.17–44.77 µM) and A549 (IC50, 31.43–77.05 µM) cell lines [53]. Structural optimization analysis revealed that epiremisporine H (19), bearing 4-methyl and 11-hydroxyl substitutions, demonstrated enhanced potency compared to methyl-deficient analogs 13–18 [52,53]. Concurrently, sponge-associated Penicillium citrinum SCSIO41017 yielded coniochaetone M (20), which showed broad-spectrum cytotoxic activity against the SF-268, MCF-7, HepG2, and A549 cell lines, with IC50 values ranging from 43.0 to 16.0 µM [51]. The marine-derived Penicillium sp. MCCC3A00228 produced D-arabinitol-anofinicate (21), a structurally unique compound demonstrating modest transcriptional activation of the orphan nuclear receptor Nur77 [54]. This receptor, encoded by NR4A1, has been identified as a critical factor in breast cancer suppression [55].
3.1.4. Pyrones
Kojic acid (22) from Penicillium chrysogenum S003 exhibited negligible cytotoxicity against multiple cancer cell lines (A-549, HeLa, DU-145, HepG2, MCF-7), with all IC50 values > 100 µM [56]. Deep-sea Penicillium cyclopium SD-413 produced cyclopiumolides A and B (23 and 24), exhibiting moderate activity against SF126, FaDu, and TE-1 cells, with IC50 values ranging from 5.86 to 17.05 µM [57]. Molecular docking studies revealed a preferential binding affinity for PARP1 (PDB: 4RV6). Compound 23 formed hydrogen bonds with Gln707, Ser711, Ser714, and Asp993, while compound 24 interacted with Gly863, Ser864, Tyr896, and Ser904, which accounts for their differing bioactivities [57]. Penicillium sumatraense SC29 associated with Sargassum cristaefolium yielded penisterines C and D (25 and 26), with the latter showing EPC growth inhibition (IC50, 28.5 µg/mL) and anti-angiogenic effects in zebrafish models [58]. Deep-sea-derived Penicillium citreonigrum MCCC3A00169 produced pyrenocine A (27) and citreoviridin (28), both of which demonstrated significant antiproliferative activity against HeLa cells, with IC50 values of 5.4 µM and 0.7 µM, respectively [59]. Penicillium chrysogenum MCCC3A00292 afforded peniciversiol A (29), selectively inhibiting BIU-87 cells (IC50, 10.21 µM), while asperdemin (30) showed moderate activity against esophageal (ECA109, IC50 > 20 µM), bladder (BIU-87, IC50 > 20 µM), and hepatic (BEL7402, IC50 12.75 µM) cells [60]. Penicillium sp. XL-01 yielded verrucosidin derivatives 31–35, with 35 demonstrating broad-spectrum cytotoxicity against the HeLa, MDA-MB-231, MCF-7, MGC-803, and A-549 cell lines, with IC50 values ranging from 1.91 to 3.91 µM. Notably, 31 and 33 exhibited selective cytotoxicity against MGC-803 (0.96 and 1.14 µM) cells, surpassing cisplatin (1.15 –1.25 µM), while maintaining low toxicity toward NRK-52E normal cells (IC50, 18.3–46.7 µM) [61]. Furthermore, Penicillum citreonigrum XT20-134 produced 2-hydroxyl-3-pyrenocine-thio propanoic acid (36), showing moderate activity against the Bel 7402 and HT 1080 cell lines, with IC50 values of 7.63 and 10.22 µM, respectively [62].
3.1.5. Fatty Acids and Esters
The marine-derived endophytic fungus Penicillium oxalicum 2021CDF-3, isolated from Rhodomela confervoides, produced oxalihexane A (37), which demonstrated potent anti-pancreatic carcinoma activity against PATU 8988T cells (93% inhibition at 20 µM) through Wnt5a/cyclin D1 pathway modulation, inducing apoptosis via cyclin protein dysregulation [63]. Penicillium sp. ZZ1750 yielded penidifarnesylin A (38), which exhibited glioblastoma cell line inhibition against U87MG and U251 cells, with IC50 values of 5.9 and 27.6 µM, respectively [64]. A deep-sea fungal co-culture of Penicillium crustosum PRB-2 and Penicillium fellutanum HDN14-323 afforded penifellutins A and B (39 and 40), which suppressed zebrafish larval liver cell proliferation at 10 µM. Structure–activity relationship analysis identified the dicarboxylate moiety as crucial for their anti-hepatocarcinoma potential [65]. Additionally, radiclonic acid (41) showed broad-spectrum cytotoxicity against the ECA109, BIU-87, and BEL-7402 carcinoma cell lines, with IC50 values ranging from 7.70 to 13.75 µM [60].
3.1.6. Furans
Penicillium sp. LA032 afforded penicinone A (42), featuring a rare furan-fused [3,4-b].pyran-5-one scaffold, which demonstrated selective cytotoxicity against HepG2 cells (IC50, 3.87 µM), outperforming cisplatin in B16 cell inhibition (27.91 µM vs. 20.39 µM) [66]. DES-mutagenized Penicillium purpurogenum G59 produced purpurogenic acid (43), showing differential inhibition (52.7–78.8%) against K562, HL-60, HeLa, and BGC-823 cells at 100 µg/mL [67]. Additionally, penicillic acid (44) demonstrated significant cytotoxicity toward lymphoma cells (L5178Y), with an IC50 value of 8.9 µM [48].
3.1.7. Xanthone and Benzophenones
Penicillium chrysogenum AD-1540 yielded chryxanthones A and B (45 and 46), with 45 demonstrating moderate cytotoxicity against BT-549 and HeLa cells (IC50, 20.4 and 23.5 µM) and 46 showing selective inhibition of the A549 cell line (20.4 µM) [68]. Penicillium citrinum HL-5126 produced spenibenzophenone B (47), which exhibited cytotoxicity against A549 cells (IC50, 15.7 µg/mL) [69]. Additionally, deep-sea Penicillium chrysogenum MCCC3A00292 afforded 3,8-dihydroxy-4-(2,3-dihydroxy-1-hydroxymethylpropyl)-1-methoxyxanthone (48), showing differential inhibition against ECA109 (IC50 > 20 μM), BIU87 (IC50 > 20 μM), and BEL7402 carcinoma cells (IC50, 15.94 µM) [60]. The novel polyketide derivative penicixanthene E (49) was isolated from Penicillium sp. GXIMD03101, demonstrating moderate anti-pancreatic carcinoma activity against SW1990 cells, with an IC50 value of 23.8 µM [70]. 4,4’-bond secalonic acid D (50), isolated from the marine-derived fungus Penicillium pancreicum M2013714, significantly inhibited the proliferation of 22 hepatocellular carcinoma cell lines (0.484–1.384 µM) with selective tumor targeting [71].
3.1.8. Quinones
Quinones, characterized by their conjugated cyclic diketone framework featuring two carbonyl groups within an aromatic system, constitute a structurally distinctive class of marine-derived secondary metabolites with multifaceted biological roles [72]. These molecular architectures have gained prominence as privileged scaffolds in anticancer drug discovery, particularly for their adaptability in natural product-inspired targeted therapy development.
Marine-derived Penicillium spp. have yielded numerous bioactive naphthoquinones. Penicillium verruculosum XWSO1F60, isolated from a marine sponge, produced averufin (51), demonstrating notable HL60 cell line inhibition, with an IC50 value of 1.005 µM. A molecular docking study revealed strong binding affinity to α-β tubulin (1JFF, -10.2202 Kcal/mol) [73]. Penicillium brocae HDN12-143 afforded fumigatin chlorohydrin (52) and iso-fumigatin chlorohydrin (53), showing cytotoxicity toward HL60, with IC50 values of 18.63 µM and 24.83 µM, respectively [74]. Endocrocin methyl ester (54) and emodin (55) were isolated for the first time from the marine-derived fungus Penicillium sp. WP-13, and both exhibited negligible cytotoxic activity against the K562, BEL-7402, and SGC-7901 cell lines, with IC50 values ranging from 31.49 to 87.67 µM, respectively [75]. Sponge-associated Penicillium sp. SCSIO41015 produced frangula-emodin (55), exhibiting selective cytotoxic activity against human gastric cancer MGC803 cells, with an IC50 value of 5.19 µM [76]. Rugulosin A (56) demonstrated broad-spectrum cytotoxicity against QGY7701, H1299, and HCT116 cells (IC50, 17.6–21.2 µM) [54].
Deep-sea Penicillium thomii YPGA3 produced penithoketone (57), 3,5-dihydroxy-2-methoxy-1,4-naphthalenedione (58), and 2-methoxyjuglone (59). SAR studies revealed that 59 (IC50, 4.9–9.1 µM) exhibited enhanced potency over its 3-hydroxylated analog 58 across MCF7, MDAMB468, C4-2B, and C4-2B/ENZR cells [77]. Peniquinones A and B (60 and 61) were isolated from the marine fungus Penicillium sp. L129. Compound 60 showed moderate cytotoxicity against the MCF-7, U87, and PC-3 cell lines, with IC50 values ranging from 9.01 to 14.59 µM, while 61 exhibited relatively weaker cytotoxic activity, with IC50 values between 13.45 and 25.32 µM [78]. Mangrove-derived Penicillium sp. SCSIO41411 afforded embelin A (62), demonstrating cytotoxicity against PC-3 and LNCaP cells, with IC50 values of 18.69 and 31.62 µM, respectively [79]. Questiomycin A (63), isolated from the marine-derived Penicillium sp. ZZ1750, demonstrated moderate cytotoxicity (IC50, 14.13–22.56 µM) through ROS-mediated apoptosis, involving mitochondrial membrane potential reduction and caspase-3 activation [80].
3.1.9. Phenolics
Phenolic compounds, characterized by aromatic rings with hydroxyl substituents, have emerged as promising Nrf2 inhibitors for cancer chemoprevention. Nrf2, a key regulator of the oxidative stress response, represents a novel therapeutic target, with natural phenolics like curcumin and resveratrol demonstrating significant anticancer potential [81,82,83,84]. This review identifies 29 phenolics with broad-spectrum anticancer activity.
Phenol
Penicillium anacriticum KMM4685 produced β-resoantarctines A and B (64 and 66) and 8-dehydro-β-resoantarctine A (65), exhibiting cytotoxic activities against human prostate cancer cell lines LNCaP, DU145, and 22 Rv1, with IC50 values ranging from 31 to 82.5 μM [85]. Penicillium aculeatum yielded novel sulfones pensulfonoxy (67) and pensulfonamide (68), and the latter demonstrated potent MCF-7 and HCT-116 cell line inhibition (IC50, 2.18 and 6.12 µM), while 67 showed remarkable cytotoxicity toward HCT-116 (IC50, 5.23 μM) [86]. Penicillium sp. ZZ1750 produced peniresorcinosides A–E (69–73), with glycosylated alkylresorcinols 69 and 70 exhibiting moderate anti-glioma activity against U87 MG and U251 cells, with IC50 values between 4.0 and 14.1 µM. SAR studies indicated that long-chain fatty acid substitution in 71–73 reduced potency (19.4–53.0 μM) [64]. Sorbicillin (74), isolated from the deep-sea fungus Penicillium allii-sativi MCCC3A00580, induced G2-M-phase arrest in HT-29 cells through p-H3 and cyclin B1 upregulation at concentrations between 5 and 30 μM [87]. Resorcinoside A (75), isolated from Penicillium janthinellum 168CLC-17, exhibited significant cytotoxic activity against the NUGC-3 gastric cancer cell line, with a GI50 value of 9.3 µM [88].
Additionally, 3,3′-dihydroxy-5,5′-dimethyldiphenyl ether (76) demonstrated inhibitory effects against BIU-87 cells (IC50, 16.41 µM), and violaceol-II (77) showed strong inhibitory activity against ECA 109 cells (IC50, 8.95 µM). Furthermore, compounds 76 and 77 exhibited moderate inhibitory potential against multiple cancer cell lines (ECA 109, BIU-87, BEL-7402), with IC50 values exceeding 20 µM [60]. Dicitrinone F (78) and phenol acid (79) were isolated from the marine sediment-derived fungus Penicillium citrinum VM6. Compound 78 displayed broad-spectrum cytotoxicity against several cancer cell lines, including A549, MCF7, MDA-MB-231, Hela, and AGS, with IC50 values ranging from 6.7 to 29.6 µg/mL. In contrast, 79 exhibited selective cytotoxicity against the MCF7 cell line, with an IC50 value of 98.1 µg/mL [89]. Spirolaxine (80), isolated from Penicillium sp. ZYX-Z-143, showed mild cytotoxicity against BEL-7402, with an IC50 value of 34.35 µM [90].
Xanthocillin X (81), isolated from the marine-derived Penicillium sp. ZZ1750, exhibited moderate cytotoxicity (IC50, 13.65–16.33 µM) through ROS-mediated apoptosis, involving mitochondrial membrane potential reduction and caspase-3 activation [80]. Marine sediment-derived Penicillium sp. SY2107 afforded (Z)-N-(4-hydroxystyryl)formamide (82), demonstrating antiproliferative activity against U251 and U87 MG cells (IC50, 17.0 and 39.8 µM, respectively) [91]. Halociline (83), obtained from Penicillium griseofulvum, demonstrated potent SGC-7901 and HeLa cell cytotoxicity (IC50, 0.870 and 1.442 µM). Network pharmacology and molecular dynamics simulations revealed high-affinity binding to MAPK1, MMP9, and PIK3CA (ΔEtotal, –20.28 to –27.94 kcal/mol), with maintained protein structural stability and enhanced interaction strength [92].
Phenolic Acid
Penicillium chrysogenum LD-201810 afforded (2’R)-westerdijkin A (84) and (S)-(+)-11-dehydrosydonic acid (85), with 84 demonstrating HepG2 cell line inhibition (IC50, 22.0 µM) and 85 showing differential cytotoxicity against A549 and THP-1 cells (21.2 and 18.2 µM) [93]. Penicillium parvum HDN17-478 produced penicacids F-G (86–87) alongside mycophenolic acid (88) and its methyl ester (89). Compounds 88 and 89 exhibited moderate cytotoxicity across six cancer cell lines (HCT-116/BEL-7402/MGC-803/SH-SY5Y/HO-8910/HL-60), with IC50 values ranging from 1.69 to 12.98 µM, while 86–87 demonstrated mild activity (IC50, 12.61 to 26.38 μM) [94]. Penicillium chrysogenum VH17 produced 2-(2-aminopropanamido)benzoic acid (90), showing weak MCF-7 and HepG2 cell line inhibition (87.1 and 97.3 µM) [95].
Phenol Ethers
Dehydrocurvularin (91), isolated from the mangrove-derived Penicillium sumatrense MA-325, exhibited moderate cytotoxicity against the HCT 116, 786-O, 5673, and Hela cell lines, with IC50 values ranging from 3.5 to 14.9 µM. Notably, 91 exhibited superior inhibition against bladder cancer cell line 5673 (IC50, 3.5 µM) compared to cisplatin (IC50, 4.1 µM), while maintaining low toxicity toward human embryonic kidney 293T cells (an inhibition of 54.5% at 20 µM) [96]. Additionally, 5,5-dichloro-1-(3,5-dimethoxyphenyl)-1,4- dihydroxypentan-2-one (92) showed moderate cytotoxicity against the Bel7402 and HT1080 cell lines (IC50, 13.14 and 16.53 µM, respectively) [62].
3.1.10. Sorbicillinoids
Additionally, Penicillium citrinum SCSIO41402 afforded sorbicillfuran B (93), showing potent HL-60 cell line inhibition (IC50, 9.6 µM) [97]. Sorbicatechol D (94), isolated from the deep-sea fungus Penicillium allii-sativi MCCC3A00580, induced G2-M-phase arrest in HT-29 cells through p-H3 and cyclin B1 upregulation at 30 µM [87].
3.1.11. Pyridinone Derivatives
Penipyridinone B (95) was isolated from the marine-derived Penicillium sp. ZZ1750, which exhibited moderate anti-glioma activity against U87MG and U251 cells, with IC50 values of 2.45 and 11.40 µM, respectively [80].
3.1.12. Others
The marine-derived fungus Penicillium citreonigrum MCCC3A00169 produced terrein (96), which demonstrated potent cytotoxicity through multiple mechanisms. In HeLa cells, 96 induced apoptosis (IC50, 11.3 µM) and G0-G1-phase cell cycle arrest [59]. Additionally, it inhibited A549 cell proliferation while suppressing metastasis through the modulation of adhesion, migration, and invasion processes [98]. Penicillium chrysogenum S003 yielded the glycoside LAMA (97), showing limited cytotoxicity across multiple cancer cell lines (A-549/HeLa/DU-145/HepG2/MCF-7), with all IC50 values exceeding 100 µM [56].
3.2. Alkaloids
Alkaloids represent a structurally diverse class of nitrogen-containing cyclic compounds that have gained prominence in anticancer drug discovery. These natural products exert their pharmacological effects through multiple mechanisms, including topoisomerase inhibition, apoptosis induction, and the modulation of key signaling pathways involved in cell proliferation and survival [99]. The structural diversity of cytotoxic alkaloids derived from marine Penicillium spp. is demonstrated in Figure 8.
3.2.1. Cytochalasins
Cytochalasins represent a structurally unique class of fungal metabolites featuring a tricyclic core with a macrocyclic ring fused to an isoindolinone system. These polyketide–amino acid hybrid metabolites exhibit diverse biological activities [100]. Meleagrin (98) and glandicoline B (99), isolated from the deep-sea-derived Penicillium sp. YPGA11, exhibited inhibitory effects against four esophageal cancer cell lines (EC109, EC9706, KYSE70, and KYSE450), with IC50 values ranging from 25.03 to 55.37 µM [101]. SAR analysis revealed that the methoxy group in 98 conferred enhanced potency compared to the hydroxy group in 99, with 98 also exhibiting HepG2 cell line inhibition (IC50, 7.0 µM) [102].
3.2.2. Indole Alkaloids
The indole scaffold, a ubiquitous heterocycle in nature, has emerged as a privileged structure in anticancer drug discovery due to its structural diversity and multifunctionality [103]. These compounds target key oncogenic pathways through histone deacetylases (HDACs), silent information regulators, PIM kinases, DNA topoisomerases, and s-receptors. Notably, 3,5-disubstituted indoles exhibit promising PIM kinase selectivity, with C-3 and C-5 modifications enabling isoform-specific affinity modulation [103,104]. This review highlights 15 indole derivatives from marine Penicillium spp., offering insights for targeted molecular modifications in anticancer drug development.
Penicillium dimorphosporum KMM4689 yielded deoxy-14,15-dehydroisoaustamide (100), the first deoxyisoaustamide alkaloid featuring a doubly unsaturated proline ring. At non-cytotoxic concentrations, 100 specifically degrades AR-V7, resensitizing resistant prostate cancer cells to enzalutamide, thus enhancing AR-targeted therapy efficacy [105]. The deep-sea-derived fungus Penicillium sp. LSH-3-1 yielded a new compound, peniokaramine (101), which displayed cytotoxic activity against the A549 cell line, showing an inhibition rate of 53.43% at 50 µM [106]. Penicindopene A (102), a novel indole diterpene, isolated from Penicillium sp. YPCMAC1, exhibited moderate cytotoxicity against A549 and HeLa cells, with IC50 values of 15.2 µM and 20.5 µM, respectively [107]. Additionally, emindole SB (103), obtained from Penicillium sp. KFD28, demonstrated moderate cytotoxic effects against K562 cells, with an IC50 value of 18.8 µM [108].
From the marine fungus Penicillium brasilianum HBU-136, spirotryprostatin G (104), cyclotryprostatins F and G (105 and 106), spirocyclic diketopiperazine alkaloid (107), and cyclotryprostatin B (108) were isolated. Compounds 104 and 107 showed selective HL-60 cell inhibition (IC50, 6.0 and 7.9 µM), while 105, 106, and 108 demonstrated MCF-7 cytotoxicity (IC50, 5.1–10.8 µM) [109]. Deep-sea Penicillium granulatum MCCC3A00475 yielded roquefortine J (109), exhibiting HepG2 cell line inhibition (IC50, 19.5 µM) [102]. The OSMAC-based cultivation of Penicillium oxalicum 2021CDF-3, an endophyte of marine red algae, yielded asperinamide B (110) and peniochroloids A–B (111–112). Compound 110, featuring a rare 3-pyrrolidone moiety, demonstrated potent human pharyngeal squamous FADU cell line inhibition (IC50, 0.43 µM), comparable to doxorubicin (IC50, 0.07 µM). SAR analysis revealed that the ester carbonyl group in 112 enhanced A549 cytotoxicity (IC50, 15.30 µM) compared to 111 (IC50, 29.84 µM) [110]. Neomycin-resistant Penicillium purpurogenum G59 mutant strain 3-f-31 yielded penicimutanins C (113) and A (114), exhibiting broad-spectrum cytotoxicity against the K562, HL-60, HeLa, BGC-823, and MCF-7 cell lines with IC50 values between 5.0 and 11.9 µM [111].
3.2.3. Pyridine Alkaloids
Viridicatol (115), isolated from the deep-sea fungus Penicillium solitum MCCC3A00215, exhibited moderate cytotoxic activity against PANC-1, HeLa, and A549 cells, with IC50 values of 18, 19, and 24 µM, respectively [112].
3.2.4. Pyrrole and Pyrrolidine Alkaloids
Penicillium citrinum DY180712 produced perpyrrospirone A (116), featuring an unprecedented 6/5/6/8/5/13/6 oxahexacyclic scaffold with a peroxide-bridged 8,9-dioxa-2-azaspiro [4.7]dodecane core, alongside penicillione G (117). Both compounds demonstrated broad-spectrum cytotoxicity against six human tumor cell lines (MGC803/HepG2/MDA-MB-231/MCF-7/Bel-7402/HeLa), with IC50 values ranging from 2.5 to 38.9 µM [113]. Crab-associated Penicillium sp. ZZ380 yielded penicipyrroether A (118) and pyrrospirone J (119), featuring a unique 6/5/6/5 fused ring system. These compounds exhibited potent glioblastoma U87MG and U251 cell line inhibition, with IC50 values ranging from 1.64 to 17.92 µM [114]. Additionally, pyrrospirone G (120) demonstrated significant anti-glioma activity across multiple cells (U87MG/U251/SHG44/C6, IC50, 1.06–8.52 µM), while pyrrospirones H and I (121–122) showed moderate activity (IC50, 7.44–26.64 µM) [115].
3.2.5. Quinazolines and Their Analogs
Penicillium polonicum MN623481 produced polonimides A–C (123–125) alongside known quinazoline-containing piperazine diketones aurantiomides A–C (126, 128, 129) and anacine (127). Compound 127 demonstrated notable cytotoxicity against the A549, HGC-27, and UMUC-3 cell lines (IC50, 6.0–7.2 µM) [116]. Cyclopenol (130) exhibited selective cytotoxicity against BIU-87 and BEL-7402 cells (IC50, 8.34 and 7.81 µM, respectively) [60].
3.2.6. Peptides
Penicillium citrinum 2015PF07, cultured with ScCl3 (50 µM), produced novel compounds 131 and 132, demonstrating selective cytotoxicity against the HCT-115 and MCF-7 cell lines (IC50, 20 µg/mL) [117]. Tunicate-associated Penicillium sp. from the Red Sea yielded penicillatides B (133) and cyclo (R-Pro-S-Phe) (134), exhibiting selective HCT-116 cell line inhibition (IC50, 6.0 and 9.57 μg/mL, respectively) [118].
3.2.7. Thiodiketopiperazines
Penicillium ludwiglium SCSIO41408 afforded adametizines C (135) and A (136), along with DC1149B (137). These compounds exhibited 22Rv1 prostate cancer cell line inhibition (IC50, 13.0–13.9 µM), with 137 showing notable PC-3 cell cytotoxicity (IC50, 5.1 µM) and dose-dependent apoptosis induction [119].
3.3. Terpenoids
Terpenoids, the largest and most structurally diverse class of natural products, are biosynthesized via the mevalonic acid pathway with isoprene units serving as fundamental building blocks. Notably, marine-derived sesquiterpenoids exhibit diverse biological activities and contribute to approximately one-third of reported cytotoxic compounds within this chemical class [120]. Their pharmacological potential is underscored by multifaceted anticancer mechanisms, including antiproliferative, apoptotic, anti-angiogenic, and antimetastatic activities, making them particularly intriguing for drug discovery [121,122]. The structural diversity of anticancer terpenoids derived from marine Penicillium spp. is displayed in Figure 9.
3.3.1. Sesquiterpenes
Penicillium puericum MZY-202312-521 yielded inonotic acid C (138), demonstrating significant MCF-7 breast cancer cell line inhibition (IC50, 7.7 µM) [123]. Purpuride G (139), isolated from the marine fungus Penicillium minioluteum ZZ 1657, demonstrated moderate inhibitory effects on glioblastoma U251 and U87 MG cells, with IC50 values of 4.49 and 10.9 µM, respectively [124]. Additionally, decumbenones A and B (140 and 141) demonstrated ECA109 cell line inhibition (IC50, 12.41 and 15.60 µM, respectively) [60]. Seagrass-associated Penicillium yezoense KMM4679 produced 1-acetylpallidopenilline A (142), exhibiting potent MCF-7 cell line inhibition (IC50, 0.66 µM). Structure–activity relationship analysis revealed that the 1-acetyl chain is crucial for enhancing cytotoxic activity [125]. Penicillium copticola WZXY-m122-9 produced copteremophilanes D(143), E(144), G(145), and H (146), with 146 exhibiting selective A549 cell inhibition (IC50, 3.23 µM). SAR analysis revealed that C-7/C-11 olefin rearrangement in 145 reduced potency (IC50 > 10 µM), while C-12 phenylacetic acid substitution in 143 and 144 enhanced HCT-8 cell line inhibition (IC50, 5.4–7.3 µM) [126].
3.3.2. Meroterpenoids
Meroanapartines A–C (147–149), featuring unprecedented 6/5/6/6, 6/5/6/5/6, and 6/5/6/5 polycyclic systems, were isolated from the marine fungus Penicillium anacuticum KMM 4685. These compounds exhibit P-glycoprotein (P-gp)-inhibitory activity, resensitizing drug-resistant cancer cells to docetaxel and serving as promising leads for combination therapies [127]. Penicillium sp. SCSIO41512 produced penicimeroterpenoids A–C (150–152), featuring unprecedented 5/6/6/6/7 and 5/6/6/6/4 fused ring systems. These compounds demonstrated CDC25B phosphatase inhibition (IC50, 20 µM) [128]. Penicillium sp. A18 yielded penimeroterpenoid A (153), showing weak cytotoxicity against A549, HCT116, and SW480 cells (IC50, 78.63–95.54 µM) [129]. Penisimplinoid F (154), isolated from Penicillium simplicissimum 19XS15ZM-3, displayed notable cytotoxic activity against NCI-H446 cells (IC50, 6.49 µM) [130]. Andrastone A (155), obtained from the deep-sea fungus Penicillium allii-sativi MCCC3A00580, selectively inhibited HepG2 cells (IC50, 7.8 µM) through caspase-3 activation and RXRα modulation [131]. The deep-sea-derived Penicillium thomii YPGA3 produced the new austalide meroterpenoid 156, which displayed mild breast cancer cytotoxicity against MDA-MB-468 cells, with an IC50 value of 38.9 µM [132]. Stachybotrylactone B (157), isolated from the soft coral-associated Penicillium sp. SCSIO41201, demonstrated broad-spectrum cytotoxicity against leukemia (HL-60/K562/MOLT-4) and renal carcinoma (ACHN/786-O/OS-RC-2) cell lines, with IC50 values ranging from 4.12 to 23.55 µM [133]. Marine-derived Penicillium sp. TJ403-1 yielded brevione I (158), exhibiting notable cytotoxicity against the HL-60, A-549, and HEP3B cell lines (IC50, 4.92–8.60 µM). The α,β-unsaturated carbonyl moiety in its structure, hypothesized to form covalent bonds with cysteine thiol groups, is crucial for its bioactivity [134,135].
3.3.3. Diterpenoids
Penicillium sclerotiorum GZU-XW03-2 afforded diaporthein B (159), which significantly inhibited HCT116 and LOVO colorectal cancer cell proliferation and migration (IC50, 1.5 and 3.0 µM, respectively) while promoting apoptosis. Mechanistic studies revealed that 159 modulates the Hippo/YAP/TAZ and TP53/BCL-2/BAX pathways, impairing mitochondrial function in cancer cells without significantly affecting normal intestinal epithelial cells [136]. Additionally, deep-sea-derived Penicillium sp. YPGA11 afforded conidiogenol D (160) and conidiogenone C (161), which demonstrated inhibitory effects on five esophageal cancer cell lines (EC109, EC9706, KYSE30, KYSE70, and KYSE450), with IC50 values ranging from 27.05 to 54.7µM [101].
3.4. Steroids
The steroid 22-triene-3,5-diol (162), discovered from Penicillium leveling N33.2, showed cytotoxic activity against HepG2, A549, and MCF-7 cancer cells (IC50, 2.89–18.51 µg/mL) alongside pancreatic lipase and α-glucosidase inhibition [137]. Deep-sea Penicillium solarum MCCC3A00215 yielded solitumergosterol A (163), a C30 steroid with a 6/6/6/6/5 pentacyclic skeleton showing MDA-MB-231 cell inhibition (44.1% at 20 µM) [138]. Ergosterol (164) and epidioxyergosterol (165), isolated from Penicillium chrysogenum strain S003, exhibited moderate cytotoxic activity against the A549, DU-14, MCF-7, and HepG 2 cell lines, with IC50 values ranging from 2.89 to 21.26 µM [56].
16α-Methylpregna-17α,19-dihydroxy-(9,11)-epoxy-4-ene-3,18-dione-20-acetoxy (166), derived from the sponge-associated Penicillium citrinum SCSIO41017, exhibited moderate cytotoxic activity against four tumor cell lines (SF-268, MCF-7, HepG-2, and A549), with IC50 values ranging from 13.5 to 18.0 µM [51]. Penicisteroids E (167), G (168), H (169), A (170), and C (171), isolated from the deep-sea fungus Penicillium granulatum MCCC3A00475, demonstrated selective cytotoxicity against A549, BIU-87, BEL-7402, ECA-109, Hela-S3, and PANC-1 cells, with IC50 values between 4.1 and 14.4 µM. Further studies revealed that compounds 167 and 170 could induce apoptosis via an RXRα-dependent mechanism by modulating the transcriptional expression of retinoid X receptor (RXR) α and promoting the cleavage of poly (ADP-ribose) polymerase (PARP), acting as effective RXRα binders with Kd values of 13.8 and 12.9 µM, respectively [139]. Additionally, isonuatigenin I (172) and penicisteroid A (173) demonstrated HepG2 cell line inhibition (IC50, 8.6 and 8.2 µM, respectively) [102], while 5α,6α-epoxy-(22E,24R)-ergosta-8(14),22-diene-3β,7α-diol (174) showed mild cytotoxicity against HepG2, A549, and MCF7 cells (IC50, 29.4–36.72 µM) [95]. The molecular architectures of anticancer peptides derived from marine Penicillium spp. are delineated in Figure 10.
The cytotoxic compounds isolated from marine Penicillium spp., including their names, numbers, source, biological activities, and associated references, are comprehensively summarized in Table 1.
4. Drugability Assessment
4.1. Dicitrinones G
The tangeretin dimer dicitrinone G (8) has exhibited potent antiproliferative effects against pancreatic cancer through multimodal mechanisms, addressing the critical clinical challenge of limited therapeutic options for this malignancy. In cytotoxicity evaluations using doxorubicin hydrochloride as the positive control (IC50, 18.24 μM), dimer 8 demonstrated superior activity toward BxPC-3 cells (IC50, 12.25 μM), indicating enhanced pharmacological efficacy compared to conventional chemotherapeutics [50,140]. Notably, its cytotoxic profile in PANC-1 cells (IC50, 24.33 μM) paralleled that of doxorubicin (IC50, 24.00 μM), suggesting cell line-dependent therapeutic variations [50,140]. In xenograft tumor models, 8 combined with 5-fluorouracil (5-FU) showed no toxicity in major organs (heart, liver, spleen, lungs, kidneys), indicating superior safety compared to tangeretin [141]. Mechanistic studies revealed that 8 inhibits pancreatic cancer angiogenesis via the Notch1 signaling pathway, as evidenced by reduced CD31 expression in tumor tissues. Additionally, in human umbilical vein endothelial cells (HUVECs), 8 suppressed proliferation and angiogenesis, further supporting its anti-tumor-vascularization effects [140] Under hypoxic conditions, 8 reduced interleukin-18 (IL-18) levels in a BXPC-3 cell culture medium. The combination of IL-18 blocking agent (IL-18 BP) with the hypoxic BXPC-3 conditioned medium (CM) confirmed that 8 inhibits pancreatic cancer angiogenesis by suppressing IL-18 release. Furthermore, 8 decreased NLRP3 inflammasome activation, as shown by reduced NLRP3 and caspase-1 p20 expression in tumor tissues treated with 8 and 5-FU. Genetic knockout of NLRP3 in BXPC-3 cells (gNLRP3) demonstrated that 8 inhibits angiogenesis by suppressing NLRP3 inflammasome assembly [140]. Given that NLRP3 inflammasome activation and IL-18 production are critical in pancreatic cancer progression [142,143] and considering IL-18’s role as a CXCR1/2 ligand promoting tumorigenesis and angiogenesis [144,145,146,147], 8 represents a promising marine-derived therapeutic candidate. Its ability to inhibit IL-18/NLRP3-regulated NICD suggests potential for microvascular-targeted pancreatic cancer treatment strategies [140].
4.2. Penitrem A
Penitrem A (175), an indole diterpenoid alkaloid (Figure 11) from marine-derived Penicillium commune GS20, demonstrates potent antiproliferative, antimigratory, and anti-invasive bioactivities against human breast cancer cells. This compound induces G1-phase cell cycle arrest by upregulating the cyclin-dependent kinase inhibitor p27 [148,149]. As a novel Wnt/β-catenin pathway inhibitor, 175 significantly reduces total β-catenin expression in MDA-MB-231 cells, effectively blocking breast cancer cell proliferation and migration both in vitro and in vivo [150,151,152]. Recent advances in Wnt/β-catenin-targeted drug development have highlighted the clinical translatability of such inhibitors. Notably, E7386—an orally bioavailable and selective inhibitor disrupting the β-catenin/CREB-binding protein (CBP) interaction—has emerged as a promising agent. Preclinical studies revealed that E7386 blocks Wnt/β-catenin signaling in HEK 293 cells and APC-mutant human gastric cancer ECC10 cells, with minimal off-target effects [153]. These findings align with the growing recognition of β-catenin/CBP complex inhibitors as a viable strategy to circumvent limitations of upstream Wnt pathway targeting, particularly in tumors driven by APC mutations.
Additionally, 175 functions as a BK channel antagonist, exhibiting antiproliferative effects in BK channel-overexpressing breast cancer subtypes. It synergistically enhances the efficacy of HER-targeted drugs (lapatinib and gefitinib) through STAT3 and p27 pathway modulation, offering promising strategies to overcome targeted therapy resistance [149]. These multifaceted mechanisms position 175 as a promising lead compound for breast cancer therapeutics, particularly in overcoming drug resistance and enhancing targeted therapy sensitivity.
4.3. Penicisulfuranol A
Penicisulfuranol A (176), an epipolithiodioxopiperazine (ETP) alkaloid (Figure 11) from mangrove-derived Penicillium janthinellum HDN13-309, demonstrated potent cytotoxicity against HeLa and HL-60 cells, with IC50 values of 0.5 µM and 0.1 µM, respectively. Notably, its potency was comparable to the positive control adriamycin (IC50 = 0.5 µM and 0.2 µM for HeLa and HL-60, respectively) [154]. Mechanistic studies revealed that 176 is a novel C-terminal inhibitor of heat shock protein 90 (Hsp90), disrupting its molecular chaperone function independent of the ATP-binding domain. As a key regulator of over 200 client proteins involved in cell growth signaling, Hsp90 represents a promising anticancer target. The clinical validation of this approach was recently demonstrated by the 2022 approval of pimitespib (Jeselhy®) by Taiho Pharmaceutical, an oral Hsp90α/β inhibitor for chemotherapy-refractory gastrointestinal stromal tumors (GISTs) [155]. Unlike pimitespib and other N-terminal inhibitors, 176 significantly reduced Hsp90 client protein levels without inducing Hsp70 expression, inducing apoptosis in HCT116 cells in vitro and in vivo while inhibiting xenograft tumor growth. Compound 176 inhibits Hsp90 C-terminal dimerization, prevents ADH protein disaggregation, and disrupts co-chaperone interactions. The disulfide bond in 176 was identified as crucial for Hsp90 inhibition, binding to cysteine residues near the amino acid region [156]. Extensive synthetic studies have focused on spirocyclic diketopiperazine intermediates of 176 [157]. As a novel Hsp90 C-terminal inhibitor, 176 represents a promising lead for investigating Hsp90 biology and developing colorectal cancer therapeutics.
4.4. Secalonic Acid D
Secalonic acid D (SAD, 177), a polyketide mycotoxin produced by the marine-derived fungus Penicillium oxalicum, exhibited representative bioactivity among secondary metabolites from marine fungi. Pharmacological studies demonstrated its potent cytotoxicity against K562, A549, and P388 tumor cell lines (IC50, 0.03–5.76 µM), while showing significantly weaker activity against BEL-7402 hepatoma cells (IC50, 15.50 µM), indicating remarkable tumor-selective efficacy. Notably, its effective dose in murine models was over 50-fold lower than the teratogenic threshold, highlighting a favorable therapeutic window [158,159]. Further investigations revealed potent cytotoxicity of 177 against HL-60 and K562 cells, with IC50 values of 0.38 µM and 0.43 µM, respectively. Mechanistically, 177 enhanced the kinase activity of glycogen synthase kinase-3β (GSK-3β) by promoting dephosphorylation at Ser9, thereby triggering ubiquitin-proteasome-dependent degradation of β-catenin. This process disrupted the transcriptional activation of the Wnt/β-catenin signaling pathway, downregulated the oncogene c-Myc, and ultimately induced G1-phase cell cycle arrest in HL-60 and K562 leukemia cells [160]. Additionally, 177 acted as a novel DNA topoisomerase I (topo I) inhibitor via a non-covalent binding mechanism, with a minimum inhibitory concentration (MIC) of 0.4 µM. Unlike camptothecin (CPT), which stabilized topo I-DNA covalent complexes to induce DNA damage, 177 selectively blocked the dynamic interaction between topo I and DNA substrates, thereby mitigating genomic toxicity risks. Its dose-dependent inhibition correlated with molecular conformational flexibility, target-binding affinity, and intracellular metabolic stability [161]. The non-covalent mode of action positions 177 as a promising candidate for optimized drug delivery systems, such as nanocarriers or prodrug designs, to enhance tumor-targeted efficacy while reducing off-target effects.
4.5. 4,4′-Bond Secalonic Acid D
4,4’-Bond secalonic acid D (50), a marine fungal metabolite, demonstrated notable antiproliferative activity across 22 human cancer cell lines (BGC-823, SGC-7901, HGC-27, EC9706, KYSE450, CNE1, CNE2, SW620, SW480, LOVO, HuH-7, PLC/PRF/5, SK-HEP, HeLa, A549, SK-MES-1, SPC-A1, 95D, Jeko-1, Raji, U937, A375, HFF, H22) with IC50 values ranging from 0.484 to 1.384 µM [71]. Notably, 50 showed preferential cancer cell targeting with minimal cytotoxicity against normal human foreskin fibroblasts (HFFs). Mechanistic studies revealed that 50 induced mitochondria-mediated apoptosis by modulating the Bcl-2/Bax protein ratio. It also inhibited side population (SP) cell growth in hepatocellular carcinoma models (PLC/PRF/5, HuH-7) by downregulating ATP-binding cassette superfamily G member 2 (ABCG2) expression. Furthermore, 50 suppressed SP cell invasion and migration through matrix metalloproteinase-9 (MMP-9) downregulation and metalloproteinase-1 (TIMP-1) upregulation. In vivo experiments using the H22 hepatocellular carcinoma mouse model confirmed its anti-lung metastasis effects by suppressing MMP-9 suppression [162]. Its mechanistic versatility contrasts with yet complements targeted agents like venetoclax—a clinically validated BCL-2 inhibitor that achieved therapeutic efficacy in acute myeloid leukemia (AML) through selective apoptotic induction. While venetoclax has demonstrated success in both preclinical xenograft models and clinical settings, its application remains restricted to hematological malignancies [163]. In contrast, 50 exhibited a broader anticancer spectrum, effectively targeting solid tumors like HCC while maintaining favorable selectivity between malignant and normal cells—a critical advantage given the dose-limiting toxicities observed with venetoclax in non-leukemic tissues.
5. Discussion
5.1. Chemical Diversity and Structural Features of Marine-Derived Penicillium Metabolites
Polyketides (1–97, 177) constitute the largest class (55.4%) of secondary metabolites from the Penicillium genus, exhibiting anticancer, antibacterial, antiviral, and antioxidant properties. Phenolics, representing 29.6% of polyketides, demonstrate moderate-to-potent cytotoxicity against the HL-60, HCT-116, HCT-8, and A549 cell lines. These compounds inhibit Nrf2 nuclear translocation, reducing tumor cell resistance to chemotherapy. Their combination with other anticancer agents enhances sensitivity through Nrf2 pathway inhibition and HO-1 downregulation, highlighting their potential as chemopreventive agents or combination therapies [82,164]. Alkaloids (98–137, 175, 176), characterized by nitrogen, sulfur, and oxygen heteroatoms, often exhibit anticancer activity through DNA interactions. Indole alkaloids dominate this class, with 50% being di- or trisubstituted, primarily at C2 and C3 positions. Pyrrolidine-based trisubstituted alkaloids show significant cytotoxicity against glioma and gastric cancer cells. Metal complexes of alkaloids have emerged as potent anticancer agents, with nitrogen atoms enabling multiparameter optimization and pharmacological enhancements exceeding 1000-fold in some cases [165,166,167]. Triterpenoids (138–161), typically featuring α-methylene-γ-lactone structures, exhibit mild anticancer activity by modulating redox balance and signaling pathways, leading to cell cycle arrest and apoptosis induction [168]. Steroids (162–174) exhibit selective cytotoxicity against malignant cells, showing potential applications in hormone-based therapies, cancer vaccine development, and synergistic combination regimens. Furthermore, steroid–drug conjugates significantly enhance therapeutic efficacy in anticancer treatment through three synergistic mechanisms: improved target specificity, enhanced cellular delivery capabilities, and optimized therapeutic safety profiles, while concurrently exerting multi-pathway therapeutic effects through the strategic modulation of key cellular signaling pathways—consequently reducing systemic toxicity relative to their non-conjugated counterparts [169]. Despite their potential, many marine-derived compounds face challenges in clinical translation due to toxicity or poor bioavailability. Strategies such as nanoparticle delivery, antibody–drug conjugates, and network-based multi-target drug design are essential for enhancing stability, specificity, and efficacy [170,171,172,173].
5.2. Current Status of Marine Drug Development
Marine-derived antitumor drugs have gained significant attention, with several compounds advancing to clinical trials. BG136, a β-1,3/1,6-glucan from Durvillaea antarctica, activates innate immunity through carbohydrate receptor binding, demonstrating broad-spectrum antitumor effects [174,175]. Trabectedin (Yondelis®), derived from Ecteinascidia turbinata, is approved for soft tissue sarcoma and liposarcoma, with recent studies showing improved progression-free survival in combination with doxorubicin [176,177,178]. To date, multiple marine-derived drugs have been approved for cancer, cardiovascular diseases, and diabetes, underscoring the field’s achievements. However, the vast potential of marine natural products remains underexplored, with numerous compounds awaiting further investigation [179].
5.3. Challenges and Future Directions
Marine drug discovery faces significant hurdles, including the sparse distribution of medicinal organisms, low concentrations of active components, and complex extraction processes. The lack of efficient high-throughput screening methods further limits the discovery of novel compounds. Additionally, the intricate mechanisms and toxicity profiles of marine-derived substances necessitate extensive pharmacological and toxicological studies, making the development process time-consuming and costly [180].
Future research should focus on artificial cultivation, marine biobanks, and biosynthetic pathway exploration to enable sustainable resource utilization. High-throughput screening, combined with biosynthetic and chemical synthetic methods, will enhance the efficiency of bioactive compound discovery. Advanced technologies such as artificial intelligence and machine learning can optimize compound structures and predict bioactivities, accelerating drug development and deepening mechanistic understanding [181]. Interdisciplinary integration and innovative 3D cell culture models will improve screening mechanisms, while automation and software advancements will promote the development of marine-derived therapeutics, ensuring that their full potential is realized [182].
The exploration of biosynthetic gene clusters (BGCs) as reservoirs of novel bioactive molecules has established genome mining as a cornerstone of marine natural product discovery [183]. Advances in high-throughput sequencing have catalyzed exponential growth in marine genomic datasets, enabling the precise identification of signature biosynthetic genes and enzymatic domains through multi-sequence alignment and conserved structural motif analysis [184,185]. Notably, over 70% of marine-derived BGCs remain transcriptionally silent under standard laboratory conditions, necessitating activation through environmental or metabolic cues. To address this challenge, multidimensional activation strategies have emerged: (1) microenvironmental stress induction via physicochemical parameter optimization (e.g., salinity gradients, temperature shifts); (2) microbial co-culturing to simulate ecological interactions; and (3) epigenetic modulation using histone deacetylase inhibitors or chromatin remodelers. These approaches, integrated with comparative genomics, have successfully unlocked cryptic clusters, yielding marine polyketides, nonribosomal peptides, and hybrid compounds with unprecedented scaffolds, exemplified by the discovery of 95 novel compounds from marine actinomycetes and fungi in recent studies [186,187].
Bioinformatic tools, particularly hidden Markov model (HMM)-based algorithms, now achieve >90% accuracy in BGC prediction [188]. Coupled with metabolic network reconstruction, these tools elucidate module organization and substrate specificity, as demonstrated by the identification of 4000+ novel BGCs in the Ocean Microbiomics Database (OMD), including ribosomally synthesized and post-translationally modified peptides (RiPPs) from uncultivated marine Candidatus Eremiobacterota [189]. Synthetic biology further amplifies this potential: CRISPR-Cas9-mediated promoter engineering and large DNA fragment assembly enable heterologous BGC reconstitution [190]. For instance, the EQCi dynamic regulation system in Streptomyces enhanced rapamycin production by 660% [191], while the modular refactoring of fungal terpene clusters in Aspergillus oryzae accelerated the discovery of anti-inflammatory mangicol J [192]. Such integration of “BGC–metabolic flux” not only deciphers evolutionary drivers of marine microbial secondary metabolism but also establishes a foundation for combinatorial biosynthesis [185,193].
Future directions emphasize spatiotemporal pathway activation via synthetic regulatory libraries and biosensor-coupled dynamic systems. To mitigate cytotoxicity, metabolic engineering optimizes precursor supply, as evidenced by riboflavin cofactor engineering boosting caerulomycin A production 14.6-fold [194]. For bioavailability challenges, nanocarrier delivery systems—such as DNA-barcoded renal-targeting nanoparticles demonstrated in recent studies—offer solutions to overcome efflux transporters like P-gp, as seen in oral paclitaxel formulations [127]. These interdisciplinary strategies bridge discovery and scalable biomanufacturing, positioning marine natural products as sustainable drug development pipelines.
6. Conclusions and Future Perspectives
This review highlights 177 marine-derived anticancer secondary metabolites from Penicillium spp. identified between 2018 and 2024. Predominantly isolated from marine sediments, corals, sponges, and sea water, these compounds were primarily sourced from Penicillium citrinum, Penicillium chrysogenum, and Penicillium granulatum. This review systematically examines their chemical diversity, anticancer activities, and pharmacological potential, with polyketides and alkaloids constituting over 50% of the identified structures, followed by terpenoids and steroids. All compounds demonstrated cytotoxic activity, with dicitrinone G (8), 4,4’-bond secalonic acid D (50), penitrem A (175), penicisulfuranol A (176), and secalonic acid D (177) exhibiting particularly promising drug-like properties and unique mechanisms of action. While detailed anticancer data remain limited for many compounds, their structural diversity underscores their potential as scaffolds for novel drug design or combination therapies. This compilation provides a valuable resource for selecting candidates for further investigation and emphasizes the untapped potential of marine-derived natural products in anticancer drug discovery. Future research should leverage advanced technologies such as high-throughput screening, synthetic biology, and artificial intelligence to accelerate the exploration of these marine resources and elucidate their pharmacological mechanisms.
Conception and design of the manuscript: Z.Z.; search of the literature and analysis of the information: S.Z. and Y.W.; drafting and revision of the manuscript: S.Z. and H.W.; editing of the manuscript: Z.C. and C.S.; finalization and approval of the revised manuscript for submission: Z.Z. and Z.C. All authors have read and agreed to the published version of the manuscript.
Not applicable.
No new data were created or analyzed in this study. Data sharing is not applicable to this article.
The authors declare no conflict of interest.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Figure 1 Distribution of selected cytotoxic compounds from marine-derived Penicillium spp.
Figure 2 Annual statistics of Penicillium-derived cytotoxic compounds.
Figure 3 Sources of selected cytotoxic compounds from marine-derived Penicillium spp.
Figure 4 Chemical class distribution of selected marine-derived Penicillium secondary metabolites.
Figure 5 Chemical class distribution of selected polyketides produced by Penicillium spp.
Figure 6 The chemical structures of cytotoxic polyketides (1–50).
Figure 7 The chemical structures of cytotoxic polyketides (51–97).
Figure 8 The chemical structures of cytotoxic alkaloids (98–137).
Figure 9 The chemical structures of anticancer terpenoids (138–161).
Figure 10 The chemical structures of anticancer steroids (162–174).
Figure 11 The chemical structures of compounds 175–177.
List of compounds with anticancer activity in marine Penicillium spp.
| Compounds | Source | Producing Strain | Cell Lines | IC50/GI50/Inhibition Rate/Mechanism | References |
|---|---|---|---|---|---|
| Penidioxolane C (1) | Marine sponge Holoxea sp. | Penicillium sclerotiorum E23 Y-1A | K562, BEL-7402, SGC-7901, A549, Hela | 23.94–60.66 µM | [ |
| 8a-epi-hypocrellone A (2) | Marine alga Grateloupia sp. | Penicillium sclerotiorum | SH-SY5Y | 35.6 µM | [ |
| 8 α-epi-eupenicilazaphilone C (3) | 73.2 µM | ||||
| Hypocrellone A (4) | >100 µM | ||||
| Eupenicilazaphilone C (5) | 95.2 µM | ||||
| Brominated azaphilone A (6) | Marine sponge Agelas oroides | Penicillium canescens | / | / | [ |
| Brominated azaphilone B (7) | L5178Y, A2780 | 8.9, 2.7 µM | |||
| Dicitrinones G (8) | Starfish | Penicillium sp. GGF 16 -1-2 | BXPC-3, PANC-1 | 12.25, 24.33 µM | [ |
| Xerucitrinin A (9) | Sponge Callyspongia sp. | Penicillium citrinum SCSIO 41017 | SF-268, MCF-7, HepG-2, A549 | 13.0–115.3 µM | [ |
| Xerucitrinic acid A (10) | |||||
| Penicitrinol B (11) | |||||
| Penicitrinone A (12) | MCF-7 | 1.3 µM | |||
| Epiremisporine A (12) | Wastewater | Penicillium citrinum BCRC 09F458 | A549 | 49.15 µM | [ |
| Epiremisporine C (13) | Wastewater | Penicillium citrinum BCRC 09F458 | A549 | >100 µM | [ |
| Epiremisporine D (14) | |||||
| Epiremisporine E (15) | A549 | 43.82 µM | |||
| Epiremisporine B (16) | A549, HT-29 | 32.29, 50.88 µM | |||
| Epiremisporine F (17) | Wastewater | Penicillium citrinum BCRC 09F458 | HT-29, A549 | 44.77, 77.05 µM | [ |
| Epiremisporine G (18) | 35.05, 52.30 µM | ||||
| Epiremisporine H (19) | 21.17, 31.43 µM | ||||
| Coniochaetone M (20) | Sponge Callypongia sp. | Penicillium citrinum SCSIO 41017 | SF-268, MCF-7, HepG-2, A549 | 43.0–16.0 µM | [ |
| D-arabinitol-anofinicate (21) | Sea water | Penicillium sp. | / | Transcriptional activation of orphan nuclear receptor Nur77 | [ |
| Kojicacid (22) | Deep-sea sediment | Penicillium chrysogenum strain S003 | A-549, HeLa, DU-145, HepG2, MCF-7 | >100 µM | [ |
| Cyclopiumolide A (23) | Deep-sea sediment | Penicillium cyclopium SD-413 | SF126, FaDu, TE-1 | 5.86–17.05 µM | [ |
| Cyclopiumolide B (24) | |||||
| Penisterine C (25) | Marine brown alga Sargassum cristaefolium | Penicillium sumatraense SC 29 | EPC | 28.5 µg/mL | [ |
| Penisterine D (26) | / | Anti-angiogenic effects | |||
| Pyrenocine A (27) | Deep-sea sediment | Penicillium citreonigrum | HeLa | 5.4 µM | [ |
| Citreoviridin (28) | 0.7 µM | ||||
| Peniciversiol A (29) | Deep-sea sediment | Penicillium chrysogenum | BIU-87 | 10.21 µM | [ |
| Asperdemin (30) | ECA 109, BIU-87, BEL-7402 | >20, 12.75 µM | |||
| Nordeoxyverrucosidin (31) | Bohai Sea | Penicillium sp. XL-01 | HeLa, MDAMB-231, MGC-803 | 0.96–3.60 µM | [ |
| Norverrucosidinol acetate (32) | NRK 52 E | 18.3 µM | |||
| Deoxyverrucosidin (33) | HeLa, MDAMB-231, MGC-803 | 1.14–6.37 µM | |||
| Verrucosidinol acetate (34) | NRK 52 E | 25.0 µM | |||
| Verrucosidin (35) | HeLa, MDA-MB-231, MCF-7, MGC-803, A-549, NRK 52 E | 1.91–3.91 and 23.1 µM | |||
| 2-hydroxyl-3-pyrenocine-thio propanoic acid (36) | Marine sediments | Penicillum citreonigrum XT20-134 | Bel 7402, HT 1080 | 7.63, 10.22 µM | [ |
| Oxalihexane A (37) | Red algae Rhodomela confervoides | Penicillium oxalicum 2021CDF-3 | PATU 8988T | 93% (20 µM) | [ |
| Penidifarnesylin A (38) | Marine mud | Penicillium sp. ZZ1750 | U87MG, U251 | 5.9, 27.6 µM | [ |
| Penifellutins A (39) | Deep-sea sediment | Penicillium crustosum PR B-2, Penicillium fellutanum HDN 14 -323 | / | Suppressed zebrafish larval liver proliferation at 10 µM | [ |
| Penifellutin B (40) | |||||
| Radiclonic acid (41) | Deep-sea sediment | Penicillium chrysogenum | ECA 109, BIU-87, BEL-7402 | 7.70–13.75 µM | [ |
| Penicinones A (42) | Rhizospheric soil of mangrove ecosystem | Penicillium sp. LA 032 | HepG 2, MCF-7, B16 | 3.87, 30.01, 27.91 µM | [ |
| Purpurogenic acid (43) | / | Penicillium purpurogenum G59 | K562, HL-60, HeLa, BGC-823 | 52.7%, 78.8%, 38.4%, 35.3% (100 μg/mL) | [ |
| Penicillic acid (44) | Marine sponge | Penicillium canescens | L5178 Y | 8.9 µM | [ |
| Chryxanthone A (45) | Red marine alga Grateloupia turuturu | Penicillium chrysogenum AD-1540 | BT-549, HeLa | 20.4, 23.5 µM | [ |
| Chryxanthone B (46) | A549 | 20.4 µM | |||
| Spenibenzophenones B (47) | Mangrove | Penicillium citrinum HL-5126 | A549 | 15.7 μg/mL | [ |
| 3,8-dihydroxy-4-(2,3-dihydroxy-1-hydroxymethylpropyl)-1-methoxYxanthone (48) | Deep-sea sediment | Penicillium chrysogenum | ECA 109, BIU-87, BEL-7402 | >20 and 15.94 µM | [ |
| Penicixanthene E (49) | Mangrove | Penicillium sp. GXIMD 03101 | SW 1990 | 23.8 µM | [ |
| 4,4′-bond secalonic acid D (4,4′-SAD) (50) | Deep-sea sediment | Penicillium pancreicum | BGC-823, SGC-7901, | 0.484–1.384 µM | [ |
| Averufin (51) | Marine sponge | Penicillium verruculosum XWSO1F60 | HL60 | 1.005 µM | [ |
| Fumigatin chlorohydrin (52) | Marine sediments | Penicillium Brocae HDN-12- 143 | HL-60 | 18.63 µM | [ |
| Iso-fumigatin chlorohydrin (53) | 24.83 µM | ||||
| Endocrocin methyl ester (54) | Red snail Strombus luhuanus | Penicillium sp. WP-13 | K562, BEL-7402, SGC-7901 | 31.49–57.10 µM | [ |
| Emodin (55) | 56.78–87.67 µM | ||||
| Emodin (55) | Marine sponge | Penicillium sp. SCSIO 41015 | MGC 803 | 5.19 µM | [ |
| Rugulosin A (56) | Sea water | Penicillium sp. | QGY7701, H1299, HCT 116 | 21.2, 18, 17.6 µM | [ |
| Penithoketone (57) | Deep-sea sediment | Penicillium thomii YPGA 3 | MCF-7, MDAMB-468, C4-2B, C4-2B/ENZR | 4.9–9.1 µM | [ |
| 3,5-dihydroxy-2-methoxy-1,4-naphthalenedione (58) | >50, 38, 41, >50 µM | ||||
| 2-methoxyjuglone (59) | 4.9–9.1 µM | ||||
| Peniquinone A (60) | Rhizosphere soil of Limonium sinense | Penicillium sp. L129 | MCF-7, U87, PC 3 | 12.39, 9.01, 14.59 µM | [ |
| Peniquinone B (61) | 25.32, 13.45, 19.93 µM | ||||
| Embelin A (62) | Rhizosphere sediment of mangrove Aegiceras corniculatum | Penicillium sp. SCSIO 41411 | PC-3, LNCaP | 18.69, 31.62 µM | [ |
| Questiomycin A (63) | Marine mud | Penicillium sp. ZZ1750 | U87 M, U251 | 14.13–22.56 µM | [ |
| β-resoanaparticine A (64) | Marine brown alga Sargassum miyabei | Penicillium anacriticum KMM 4685 | LNCaP, DU 145, 22 Rv 1 | 31–82.5 µM | [ |
| 8-dehydro-β-resoantarctine A (65) | |||||
| β-resoanaparticine B (66) | |||||
| Pensulfonoxy (67) | Red alga Laurencia obtusa | Penicillium aculeatum | HCT-116 | 5.23 µM | [ |
| Pensulfonamide (68) | MCF-7, HCT-116 | 2.18, 6.12 µM | |||
| Peniresorcinoside A (69) | Marine mud | Penicillium sp. ZZ1750 | U87 MG, U251 | 4.0, 14.1 µM | [ |
| Peniresorcinoside B (70) | 5.6, 9.8 µM | ||||
| Peniresorcinoside C (71) | U87MG | 53 µM | |||
| Peniresorcinoside D (72) | 19.4 µM | ||||
| Peniresorcinoside E (73) | 22.1 µM | ||||
| Sorbicillin (74) | Sea water | Penicillium allii-sativi | HT-29 | 5 µM | [ |
| Resorcinosides A (75) | Deep-sea sediment | Penicillium janthinellum 168CLC-17 | NUGC-3 | 9.3 µM | [ |
| 3,3’-dihydroxy-5,5’-dimethyldiphenyl ether (76) | Deep-sea sediment | Penicillium chrysogenum | ECA 109, BEL-7402, BIU-87 | >20 and | [ |
| Violaceol-II (77) | BIU-87, BEL-7402, ECA 109 | >20 and 8.95 µM | |||
| Dicitrinone F (78) | Marine sediment | Penicillium citrinum VM6 | A549, MCF 7, MDA-MB-231, Hela, AGS | 6.7–29.6 µg/mL | [ |
| Phenol acid (79) | MCF 7 | 98.1 µg/mL | |||
| Spirolaxine (80) | Arthropod (Dardanus scutellatus) | Penicillium sp. ZYX-Z-143 | BEL-7402 | 34.35 µM | [ |
| Xanthocillin X (81) | Marine mud | Penicillium sp. ZZ1750 | U87 M, U251 | 13.65–16.33 µM | [ |
| (Z)-N-(4-hydroxystyryl)formamide (82) | Marine sediments | Penicillium sp. SY2107 | U251, U87 MG | 17.0, 39.8 µM | [ |
| Halociline (83) | / | Penicillium griseofulvum. | SGC-7901, HeLa | 0.870, 1.442 µM | [ |
| (2’R)-westerdijkin A (84) | Marine red alga | Penicillium chrysogenum LD-201810 | HepG 2 | 22.0 µM | [ |
| (S)-(+)-11-dehydrosydonic acid (85) | A549, THP-1 | 21.2, 18.2 µM | |||
| Penicacid F (86) | Marine sediments | Penicillium parvum HDN17-478 | HCT-116, BEL-7402, MGC-803, SH-SY 5 Y, HO-8910, HL-60 | 12.61–26.38 µM | [ |
| Penicacid G (87) | |||||
| Mycophenolic acid (88) | 1.69–12.98 µM | ||||
| Mycophenolic methyl ester (89) | |||||
| 2-(2-aminopropanamido)benzoic acid (90) | Soft coral | Penicillium chrysogenum VH 17 | MCF 7, HepG 2 | 87.17, 97.32 µM | [ |
| Dehydrocurvularin (91) | Marine mangrove Bruguiera sexangular | Penicillium sumatrense MA-325 | HCT 116, 786-O, 5673, Hela | 3.5–14.9 µM | [ |
| 5,5-dichloro-1-(3,5-dimethoxyphenyl)-1,4-dihydroxypentan-2-one (92) | Marine sediments | Penicillum citreonigrum XT20-134 | Bel 7402, HT 1080 | 13.14, 16.53 µM | [ |
| Sorbicillfuran B (93) | Marine alga Coelarthorum sp. | Penicillium citrinum SCSIO 41402 | HL-60 | 9.6 µM | [ |
| Sorbicatechol D (94) | Sea water | Penicillium allii-sativi | HT-29 | 30 µM | [ |
| Penipyridinone B (95) | Marine mud | Penicillium sp. ZZ1750 | U87 M, U251 | 2.45, 11.40 µM | [ |
| Terrein (96) | Marine sediments | Penicillium citreonigrum | HeLa | 11.3 µM | [ |
| LAMA (97) | Marine mud | Penicillium chrysogenum strain S003 | A-549, HeLa, DU-145, HepG2, MCF-7 | >100 µM | [ |
| Meleagrin (98) | Marine sediments | Penicillium sp. YPGA11 | EC109, EC9706, KYSE70, KYSE450, HepG2 | 25.03–36.93 and 7.0 µM | [ |
| Glandicoline B (99) | EC109, EC9706, KYSE70, KYSE450 | 30.11–55.379 μM | |||
| Deoxy-14,15-dehydroisoaustamide (100) | Soft coral | Penicillium dimorphosporum KMM 4689 | / | Enhancing AR-targeted therapy efficacy | [ |
| Peniokaramine (101) | Marine sediments | Penicillium sp. LSH-3-1 | A549 | 53.43% (50 μM) | [ |
| Penicindopene A (102) | Deep-sea water | Penicillium sp. YPCMAC1 | A549, HeLa | 15.2, 20.5 µM | [ |
| Emindole SB (103) | Bivalve mollusk (Meretrix lusoria) | Penicillium sp. KFD 28 | K562 | 18.8 µM | [ |
| Spirotryprostatin G (104) | Bohai Sea | Penicillium brasilianum HBU-136 | HL-60 | 6 µM | [ |
| Cyclotryprostatin F (105) | MCF-7 | 7.6 µM | |||
| Cyclotryprostatin G (106) | MCF-7 | 10.8 µM | |||
| Spirocyclic diketopiperazine alkaloid (107) | HL-60 | 7.9 µM | |||
| Cyclotryprostatin B (108) | MCF-7 | 5.1 µM | |||
| Roquefortine J (109) | Marine sediments | Penicillium granulatum | HepG3 | 19.5 µM | [ |
| Asperinamide B (110) | Marine red alga | Penicillium pesticum 2021 CDF-3 | FADU | 0.43 µM | [ |
| Peniochroloid A (111) | A549 | 29.84 µM | |||
| Peniochroloid B (112) | A549 | 15.30 µM | |||
| Penicimutanin C (113) | Bohai Sea | Penicillium purpurogenum G59 | K562, HL-60, HeLa, BGC-823, MCF-7 | 11.9, 5.0, 8.6, 8.7,6.0 µM | [ |
| Penicimutanin A (114) | |||||
| Viridicatol (115) | Marine mud | Penicillium solitum | PANC-1, Hela, A549 | 18, 19, 24 µM | [ |
| Perpyrrospirone A (116) | / | Penicillium citrinum DY180712 | MGC 803, HepG 2, MDA-MB-231, MCF-7, Bel-7402, HeLa | 2.5–38.9 µM | [ |
| Penicillione G (117) | |||||
| Penicipyrroether A (118) | Marine crab Pachygrapsus crassipes | Penicillium sp. ZZ380 | U87 MG, U251 | 1.64, 5.50 µM | [ |
| Pyrrospirone J (119) | 10.52, 17.92 µM | ||||
| Pyrrospirone G (120) | Marine crab Pachygrapsus crassipes | Penicillium sp. ZZ380 | U87MG, U251, SHG44, C6 | 1.06–8.52 µM | [ |
| Pyrrospirone H (121) | 7.44–26.64 µM | ||||
| Pyrrospirone I (122) | |||||
| Polonimide A (123) | Bohai Sea | Penicillium polonicum MN 623481 | A549, HGC-27, UMUC-3 | >10 µM | [ |
| Polonimide B (124) | |||||
| Polonimide C (125) | |||||
| Aurantiomide C (126) | |||||
| Anacine (127) | 6.0, 6.2, 7.2 µM | ||||
| Aurantiomide A (128) | >10 µM | ||||
| Aurantiomide B (129) | |||||
| Cyclopenol (130) | Marine sediments | Penicillium chrysogenum | BIU-87, BEL-7402 | 8.34, 7.81 µM | [ |
| Compound (131) | Marine sponge Petrosia sp. | Penicillium citrinum 2015 PF 07 | HCT 115, MCF-7 | 20 μg/mL | [ |
| Compound (132) | |||||
| Penicillatide B (133) | Red Sea tunicate Didemnum sp. | Penicillium sp. | HCT-116 | 6 µM | [ |
| Cyclo(R-Pro–S-Phe) (134) | 9.57 µM | ||||
| Adametizine C (135) | Mangrove sediment | Penicillium ludwiglium SCSIO 41408 | 22 Rv 1, PC-3 | 13.9, 44.0 µM | [ |
| Adametizine A (136) | 22 Rv 1 | 13.0 µM | |||
| DC1149B (137) | 22 Rv 1, PC-3 | 13.6, 5.1 µM | |||
| Inonotic acid C (138) | Marine alga | Penicillium puericum MZY-202312-521 | MCF-7 | 7.7 µM | [ |
| Purpuride G (139) | Deep-sea sediment | Penicillium minioluteum ZZ 1657 | U251, U87 MG | 4.49, 10.9 µM | [ |
| Decumbenone A (140) | Marine sediments | Penicillium chrysogenum | ECA 109 | 12.41 µM | [ |
| Decumbenone B (141) | 15.60 µM | ||||
| 1-acetylpallidopenilline A (142) | Marine grass | Penicillium yezoense KMM 4679 | MCF-7 | 0.66 µM | [ |
| Copteremophilane D (143) | Sponge of Xestospongia testudinaria | Penicillium copticola WZXY-m122-9 | HCT-8 | 5.4 µM | [ |
| Copteremophilane E (144) | HCT-8 | 7.3 µM | |||
| Copteremophilane G (145) | A549 | >10 µM | |||
| Copteremophilane H (146) | A549 | 3.23 µM | |||
| Meroanapartine A (147) | Marine | Penicillium anacuticum KMM 4685 | / | P-gp-inhibitory activity | [ |
| Meroanapartine B (148) | |||||
| Meroanapartine C (149) | |||||
| Penicimeroterpenoid A (150) | Soft coral | Penicillium sp. SCSIO 41512 | CDC 25 B | 20 µM | [ |
| Penicimeroterpenoid B (151) | |||||
| Penicimeroterpenoid C (152) | |||||
| Penimeroterpenoid A (153) | Marine sediments | Penicillium sp. A18 | A549, HCT 116, SW 480 | 82.61, 78.63, 95.54 µM | [ |
| Penisimplinoid F (154) | Sponge | Penicillium simplicissimum 19 XS 15 ZM-3 | NCI-H446 | 6.49 µM | [ |
| Andrastone A (155) | Deep-sea water | Penicilliumallii-sativi | HepG 2 | 7.8 µM | [ |
| Austalide Y (156) | Sea water | Penicillium thomii YPGA 3 | MDA-MB-468 | 38.9 μM | [ |
| Stachybotrylactone B (157) | Soft coral | Penicillium sp. SCSIO 41201 | HL-60, K562, MOLT-4, ACHN, 786-O, OS-RC-2 | 4.12–23.55 µM | [ |
| Breviones I (158) | Soft coral | Penicillium sp. TJ403 -1 | HL-60, A-549, HEP 3B | 4.92, 8.60, 5.50 µM | [ |
| Diaporthein B (159) | Intestinal tract of Onchidium struma | Penicillium sclerotiorum GZU-XW 03 -2 | HCT 116, LOVO | 1.5, 3 µM | [ |
| Conidiogenol D (160) | Marine sediments | Penicillium sp. SY2107 | EC109, EC9706, KYSE30, KYSE70, KYSE450 | 36.80–54.7 µM | [ |
| Conidiogenone C (161) | 27.05–42.13 µM | ||||
| 22-triene-3,5-diol (162) | Marine grass | Penicillium leveling N33.2 | Hep-G2, A549, MCF-7 | 2.89–18.51 µg/mL | [ |
| Solitumergosterol A (163) | Marine sediments | Penicillium solarum | MB231 | 44.1% (20 μM) | [ |
| Ergosterol (164) | Marine sediments | Penicillium chrysogenum strain S003 | A-549, DU-14, MCF-7, HepG 2 | 21.26, 1.50, 16.95, 2.89 µM | [ |
| Epidioxyergosterol (165) | 19.3, 6.10, 13.6, 3.07 µM | ||||
| 16a-methylpregna-17a,19-dihydroxy-(9,11)-epoxy-4-ene-3,18-dione-20-acetoxy (166) | Sponge | Penicillium citrinum SCSIO 41017 | SF-268, MCF-7, HepG-2, A549 | 13.5–18.0 µM | [ |
| Penicisteroid E (167) | Marine sediments | Penicillium granulatum | A549, BIU-87, BEL-7402, ECA-109, Hela-S3, PANC-1 | 14.4–4.1 µM | [ |
| Penicisteroid G (168) | |||||
| Penicisteroid H (169) | |||||
| Penicisteroid A (170) | |||||
| Penicisteroid C (171) | |||||
| Isonuatigenin I (172) | Marine sediments | Penicillium granulatum | HepG2 | 8.6 µM | [ |
| Penicisteroid A (173) | 8.2 µM | ||||
| 5 α, 6 α-epoxy-(22 E, 24 R)-ergosta-8(14), 22-diene-3 β,7 α-diol (174) | Soft coral | Penicillium chrysogenum VH17 | HepG2, A549, MCF 7 | 29.43, 33.02, 36.72 µM | [ |
1. Bray, F.; Laversanne, M.; Sung, H.; Ferlay, J.; Siegel, R.L.; Soerjomataram, I.; Jemal, A. Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA-Cancer J. Clin.; 2024; 74, pp. 229-263. [DOI: https://dx.doi.org/10.3322/caac.21834] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/38572751]
2. Miller, K.D.; Nogueira, L.; Devasia, T.; Mariotto, A.B.; Yabroff, K.R.; Jemal, A.; Kramer, J.; Siegel, R.L. Cancer treatment and survivorship statistics, 2022. CA-Cancer J. Clin.; 2022; 72, pp. 409-436. [DOI: https://dx.doi.org/10.3322/caac.21731] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35736631]
3. Siegel, R.L.; Giaquinto, A.N.; Jemal, A. Cancer statistics, 2024. CA-Cancer J. Clin.; 2024; 74, pp. 12-49. [DOI: https://dx.doi.org/10.3322/caac.21820] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/38230766]
4. Housman, G.; Byler, S.; Heerboth, S.; Lapinska, K.; Longacre, M.; Snyder, N.; Sarkar, S. Drug resistance in cancer: An overview. Cancers; 2014; 6, pp. 1769-1792. [DOI: https://dx.doi.org/10.3390/cancers6031769]
5. Nussinov, R.; Tsai, C.J.; Jang, H. Anticancer drug resistance: An update and perspective. Drug Resist. Update.; 2021; 59, 100796. [DOI: https://dx.doi.org/10.1016/j.drup.2021.100796]
6. Visser, K.E.D.; Joyce, J.A. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell; 2023; 41, pp. 374-403. [DOI: https://dx.doi.org/10.1016/j.ccell.2023.02.016]
7. Naeem, A.; Hu, P.; Yang, M.; Zhang, J.; Liu, Y.; Zhu, W.; Zheng, Q. Natural products as anticancer agents: Current status and future perspectives. Molecules; 2022; 27, 8367. [DOI: https://dx.doi.org/10.3390/molecules27238367]
8. Wei, W.; Khan, B.; Dai, Q.; Lin, J.; Kang, L.; Rajput, N.A.; Yan, W.; Liu, G.Y. Potential of secondary metabolites of diaporthe species associated with terrestrial and marine origins. J. Fungi; 2023; 9, 453. [DOI: https://dx.doi.org/10.3390/jof9040453]
9. Khalifa, S.A.M.; Elias, N.; Farag, M.A.; Chen, L.; Saeed, A.; Hegazy, M.F.; Moustafa, M.S.; Abd El-Wahed, A.; Al-Mousawi, S.M.; Musharraf, S.G.
10. Tamzi, N.N.; Rahman, M.M.; Das, S. Recent advances in marine-derived bioactives towards cancer therapy. Int. J. Transl. Med.; 2024; 4, pp. 740-781. [DOI: https://dx.doi.org/10.3390/ijtm4040051]
11. Zhou, L.; Zhang, J.; Zhao, K.; Chen, B.; Sun, Z. Natural products modulating MAPK for CRC treatment: A promising strategy. Front. Pharmacol.; 2025; 16, 1514486. [DOI: https://dx.doi.org/10.3389/fphar.2025.1514486] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/40110122]
12. Ullah, R.; Yin, Q.; Snell, A.H.; Wan, L. RAF-MEK-ERK pathway in cancer evolution and treatment. Semin. Cancer Biol.; 2022; 85, pp. 123-154. [DOI: https://dx.doi.org/10.1016/j.semcancer.2021.05.010] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33992782]
13. Stramucci, L.; Bossi, G. Approaching the challenges of MKK3/p38delta MAPK targeting for therapeutic purpose in colorectal cancer. J. Exp. Clin. Cancer Res.; 2019; 38, 504. [DOI: https://dx.doi.org/10.1186/s13046-019-1513-4] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31881903]
14. Wu, Q.; Wu, W.; Fu, B.; Shi, L.; Wang, X.; Kuca, K. JNK signaling in cancer cell survival. Med. Res. Rev.; 2019; 39, pp. 2082-2104. [DOI: https://dx.doi.org/10.1002/med.21574]
15. Staal, F.J.; Clevers, H.C. WNT signalling and haematopoiesis: A WNT-WNT situation. Nat. Rev. Immunol.; 2005; 5, pp. 21-30. [DOI: https://dx.doi.org/10.1038/nri1529]
16. Xu, X.; Zhang, M.; Xu, F.; Jiang, S. Wnt signaling in breast cancer: Biological mechanisms, challenges and opportunities. Mol. Cancer; 2020; 19, 165. [DOI: https://dx.doi.org/10.1186/s12943-020-01276-5]
17. Gao, Y.; Wang, J.; Meesakul, P.; Zhou, J.; Liu, J.; Liu, S.; Wang, C.; Cao, S. Cytotoxic compounds from marine fungi: Sources, structures, and bioactivity. Mar. Drugs; 2024; 22, 70. [DOI: https://dx.doi.org/10.3390/md22020070]
18. El-Seedi, H.R.; Refaey, M.S.; Elias, N.; El-Mallah, M.F.; Albaqami, F.M.K.; Dergaa, I.; Du, M.; Salem, M.F.; Tahir, H.E.; Dagliaa, M.
19. Dyshlovoy, S.A.; Honecker, F. Marine compounds and cancer: Updates 2022. Mar. Drugs; 2022; 20, 759. [DOI: https://dx.doi.org/10.3390/md20120759]
20. Staats, P.S.; Yearwood, T.; Charapata, S.G.; Presley, R.W.; Wallace, M.S.; Byas-Smith, M.; Fisher, R.; Bryce, D.A.; Mangieri, E.A.; Luther, R.R.
21. Mayer, A.M.; Glaser, K.B.; Cuevas, C.; Jacobs, R.S.; Kem, W.; Little, R.D.; McIntosh, J.M.; Newman, D.J.; Potts, B.C.; Shuster, D.E. The odyssey of marine pharmaceuticals: A current pipeline perspective. Trends Pharmacol. Sci.; 2010; 31, pp. 255-265. [DOI: https://dx.doi.org/10.1016/j.tips.2010.02.005] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20363514]
22. Pereira, R.B.; Evdokimov, N.M.; Lefranc, F.; Valentao, P.; Kornienko, A.; Pereira, D.M.; Andrade, P.B.; Gomes, N.G.M. Marine-derived anticancer agents: Clinical benefits, innovative mechanisms, and new targets. Mar. Drugs; 2019; 17, 329. [DOI: https://dx.doi.org/10.3390/md17060329] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31159480]
23. Martin, M.J.; Coello, L.; Fernandez, R.; Reyes, F.; Rodriguez, A.; Murcia, C.; Garranzo, M.; Mateo, C.; Sanchez-Sancho, F.; Bueno, S.
24. Barzkar, N.; Sukhikh, S.; Babich, O. Study of marine microorganism metabolites: New resources for bioactive natural products. Front. Microbiol.; 2023; 14, 1285902. [DOI: https://dx.doi.org/10.3389/fmicb.2023.1285902]
25. Deshmukh, S.K.; Prakash, V.; Ranjan, N. Marine fungi: A source of potential anticancer compounds. Front. Microbiol.; 2017; 8, 2536. [DOI: https://dx.doi.org/10.3389/fmicb.2017.02536]
26. Verissimo, A.C.S.; Pacheco, M.; Silva, A.M.S.; Pinto, D. Secondary metabolites from marine sources with potential use as leads for anticancer applications. Molecules; 2021; 26, 4292. [DOI: https://dx.doi.org/10.3390/molecules26144292]
27. Zhao, C.Y.; Zhu, T.H.; Zhu, W.M. New marine natural products of microbial origin from 2010 to 2013. Chinese. J. Org. Chem.; 2013; 33, pp. 1195-1234. [DOI: https://dx.doi.org/10.6023/cjoc201304039]
28. Lee, J.; Currano, J.N.; Carroll, P.J.; Joullie, M.M. Didemnins, tamandarins and related natural products. Nat. Prod. Rep.; 2012; 29, pp. 404-424. [DOI: https://dx.doi.org/10.1039/c2np00065b]
29. Beasley, V.R.; Bruno, S.J.; Burner, J.S.; Choi, B.W.; Rinehart, K.L.; Koritz, G.D.; Levengood, J.M. Fate of tritiated didemnin B in mice: Excretion and tissue concentrations after an intraperitoneal dose. Biopharm. Drug Dispos.; 2005; 26, pp. 341-351. [DOI: https://dx.doi.org/10.1002/bdd.466]
30. Ali, M.A.; Khan, A.U.; Ali, A.; Khaliq, M.; Khan, N.; Mujahid, S.; Calina, D.; Puskulluoglu, M.; Sharifi-Rad, J. Didemnins as marine-derived anticancer agents: Mechanistic insights and clinical potential. Med. Oncol.; 2025; 42, 43. [DOI: https://dx.doi.org/10.1007/s12032-024-02594-0]
31. Aspeslagh, S.; Awada, A.; Matos-Pita, A.S.; Aftimos, P.; Bahleda, R.; Varga, A.; Soria, J.C. Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors. Anticancer Drugs; 2016; 27, pp. 1021-1027. [DOI: https://dx.doi.org/10.1097/CAD.0000000000000409] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27610894]
32. Salazar, R.; Plummer, R.; Oaknin, A.; Robinson, A.; Pardo, B.; Soto-Matos, A.; Yovine, A.; Szyldergemajn, S.; Calvert, A.H. Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas. Investig. New Drugs; 2011; 29, pp. 1406-1413. [DOI: https://dx.doi.org/10.1007/s10637-010-9488-1] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20623160]
33. Liu, S.; Su, M.; Song, S.J.; Jung, J. Marine-derived Penicillium Species as producers of cytotoxic metabolites. Mar. Drugs; 2017; 15, 329. [DOI: https://dx.doi.org/10.3390/md15100329] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29064452]
34. Ma, H.G.; Liu, Q.; Zhu, G.L.; Liu, H.S.; Zhu, W.M. Marine natural products sourced from marine-derived Penicillium fungi. J. Asian Nat. Prod. Res.; 2016; 18, pp. 92-115. [DOI: https://dx.doi.org/10.1080/10286020.2015.1127230]
35. Yang, X.L.; Liu, J.P.; Mei, J.H.; Jiang, R.; Tu, S.Z.; Deng, H.F.; Liu, J.; Yang, S.M.; Li, J. Origins, structures, and bioactivities of secondary metabolites from marine-derived Penicillium fungi. Mini Rev. Med. Chem.; 2021; 21, pp. 2000-2019. [DOI: https://dx.doi.org/10.2174/1389557521666210217093517]
36. Xu, J.Z.; Yi, M.Q.; Ding, L.J.; He, S. A review of anti-inflammatory compounds from marine fungi, 2000–2018. Mar. Drugs; 2019; 17, 636. [DOI: https://dx.doi.org/10.3390/md17110636]
37. Lv, F.; Zeng, Y. Novel bioactive natural products from marine-derived Penicillium fungi: A review (2021–2023). Mar. Drugs; 2024; 22, 191. [DOI: https://dx.doi.org/10.3390/md22050191]
38. Zhang, P.; Wei, Q.; Yuan, X.; Xu, K. Newly reported alkaloids produced by marine-derived Penicillium species (covering 2014–2018). Bioorganic Chem.; 2020; 99, 103840. [DOI: https://dx.doi.org/10.1016/j.bioorg.2020.103840]
39. Koul, M.; Singh, S. Penicillium spp prolific producer for harnessing cytotoxic secondary metabolites. Anti-Cancer Drugs; 2017; 28, pp. 11-30. [DOI: https://dx.doi.org/10.1097/CAD.0000000000000423]
40. Wang, F.; Wang, K.; Cai, L.; Zhao, M.; Kirk, P.M.; Fan, G.; Sun, Q.; Li, B.; Wang, S.; Yu, Z.
41. Jones, E.B.G.; Suetrong, S.; Sakayaroj, J.; Bahkali, A.H.; Abdel-Wahab, M.A.; Boekhout, T.; Pang, K.L. Classification of marine ascomycota, basidiomycota, blastocladiomycota and chytridiomycota. Fungal Divers.; 2015; 73, pp. 1-72. [DOI: https://dx.doi.org/10.1007/s13225-015-0339-4]
42. Visagie, C.M.; Houbraken, J.; Frisvad, J.C.; Hong, S.B.; Klaassen, C.H.; Perrone, G.; Seifert, K.A.; Varga, J.; Yaguchi, T.; Samson, R.A. Identification and nomenclature of the genus Penicillium. Stud. Mycol.; 2014; 78, pp. 343-371. [DOI: https://dx.doi.org/10.1016/j.simyco.2014.09.001] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25505353]
43. Hashimoto, M.; Nonaka, T.; Fujii, I. Fungal type III polyketide synthases. Nat. Prod. Rep.; 2014; 31, pp. 1306-1317. [DOI: https://dx.doi.org/10.1039/C4NP00096J] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25182423]
44. Hang, L.; Liu, N.; Tang, Y. Coordinated and iterative enzyme catalysis in fungal polyketide biosynthesis. ACS Catalysis; 2016; 6, pp. 5935-5945. [DOI: https://dx.doi.org/10.1021/acscatal.6b01559]
45. Gao, J.M.; Yang, S.X.; Qin, J.C. Azaphilones: Chemistry and biology. Chem. Rev.; 2013; 113, pp. 4755-4811. [DOI: https://dx.doi.org/10.1021/cr300402y]
46. Zeng, Y.; Wang, Z.; Chang, W.; Zhao, W.; Wang, H.; Chen, H.; Dai, H.; Lv, F. New azaphilones from the marine-derived fungus Penicillium sclerotiorum E23Y-1A with their anti-inflammatory and antitumor activities. Mar. Drugs; 2023; 21, 75. [DOI: https://dx.doi.org/10.3390/md21020075]
47. Wang, H.C.; Ke, T.Y.; Ko, Y.C.; Lin, J.J.; Chang, J.S.; Cheng, Y.B. Anti-inflammatory azaphilones from the edible alga-derived fungus Penicillium sclerotiorum. Mar. Drugs; 2021; 19, 529. [DOI: https://dx.doi.org/10.3390/md19100529]
48. Frank, M.; Hartmann, R.; Plenker, M.; Mandi, A.; Kurtan, T.; Ozkaya, F.C.; Muller, W.E.G.; Kassack, M.U.; Hamacher, A.; Lin, W.
49. Xi, Y.D.; Wang, H.N.; Sun, L.X.; Ma, X.Y.; Zhang, S.C.; Zhang, Z. Recent advances in the structures and bioactivities of benzopyrans derived from marine fungi: A review. Front. Pharmacol.; 2024; 15, 1482316. [DOI: https://dx.doi.org/10.3389/fphar.2024.1482316]
50. Fan, H.; Shi, Z.M.; Lei, Y.H.; Si-Tu, M.X.; Zhou, F.G.; Feng, C.; Wei, X.; Shao, X.H.; Chen, Y.; Zhang, C.X. Rare carbon-bridged citrinin dimers from the starfish-derived symbiotic fungus Penicillium sp. GGF16-1-2. Mar. Drugs; 2022; 20, 443. [DOI: https://dx.doi.org/10.3390/md20070443]
51. Salendra, L.; Lin, X.; Chen, W.; Pang, X.; Luo, X.; Long, J.; Liao, S.; Wang, J.; Zhou, X.; Liu, Y.
52. Chu, Y.C.; Chang, C.H.; Liao, H.R.; Cheng, M.J.; Wu, M.D.; Fu, S.L.; Chen, J.J. Rare chromone derivatives from the marine-derived Penicillium citrinum with anti-cancer and anti-inflammatory activities. Mar. Drugs; 2021; 19, 25. [DOI: https://dx.doi.org/10.3390/md19010025] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33430124]
53. Chu, Y.C.; Chang, C.H.; Liao, H.R.; Fu, S.L.; Chen, J.J. Anti-cancer and anti-inflammatory activities of three new chromone derivatives from the marine-derived Penicillium citrinum. Mar. Drugs; 2021; 19, 408. [DOI: https://dx.doi.org/10.3390/md19080408] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34436247]
54. Wang, C.F.; Huang, X.F.; Xiao, H.X.; Hao, Y.J.; Xu, L.; Yan, Q.X.; Zou, Z.B.; Xie, C.L.; Xu, Y.Q.; Yang, X.W. Chemical constituents of the marine fungus Penicillium sp. MCCC 3A00228. Chem. Biodivers.; 2021; 18, e2100697. [DOI: https://dx.doi.org/10.1002/cbdv.202100697]
55. Yang, P.B.; Hou, P.P.; Liu, F.Y.; Hong, W.B.; Chen, H.Z.; Sun, X.Y.; Li, P.; Zhang, Y.; Ju, C.Y.; Luo, L.J.
56. Alshehri, S.O.; Malatani, R.T.; Bogari, H.A.; Noor, A.O.; Ibrahim, A.K.; Elhady, S.S.; Abdelhameed, R.F.A. Lama-1: A cerebroside isolated from the deep-sea-derived fungus Penicillium chrysogenum. Metabolites; 2020; 10, 75. [DOI: https://dx.doi.org/10.3390/metabo10020075]
57. Li, Y.H.; Yang, S.Q.; Li, X.M.; Li, X.; Wang, B.G.; Li, H.L. Cyclopiumolides A and B, unusual 13-membered macrolides from the deep sea-sourced fungus Penicillium cyclopium SD-413 with antiproliferative activities. Bioorganic Chem.; 2022; 128, 106104. [DOI: https://dx.doi.org/10.1016/j.bioorg.2022.106104]
58. Hsi, H.Y.; Wang, S.W.; Cheng, C.H.; Pang, K.L.; Leu, J.Y.; Chang, S.H.; Lee, Y.T.; Kuo, Y.H.; Huang, C.Y.; Lee, T.H. Chemical constituents and anti-angiogenic principles from a marine algicolous Penicillium sumatraense SC29. Molecules; 2022; 27, 8940. [DOI: https://dx.doi.org/10.3390/molecules27248940]
59. Zou, Z.B.; Zhang, G.; Zhou, Y.Q.; Xie, C.L.; Xie, M.M.; Xu, L.; Hao, Y.J.; Luo, L.Z.; Zhang, X.K.; Yang, X.W.
60. Niu, S.; Xia, M.; Chen, M.; Liu, X.; Li, Z.; Xie, Y.; Shao, Z.; Zhang, G. Cytotoxic polyketides isolated from the deep-sea-derived fungus Penicillium chrysogenum MCCC 3A00292. Mar. Drugs; 2019; 17, 686. [DOI: https://dx.doi.org/10.3390/md17120686]
61. Xu, Y.; Zhang, M.; Liub, Q.A.; Hua, L.D.; Lia, W.; Zhua, H.J.; Liuc, L.; Caoa, F. New verrucosidin derivatives from the marine-derived fungus Penicillium sp. XL-01. Nat. Prod. Commun.; 2018; 13, pp. 1329-1332. [DOI: https://dx.doi.org/10.1177/1934578X1801301024]
62. Tang, X.X.; Liu, S.Z.; Yan, X.; Tang, B.W.; Fang, M.J.; Wang, X.M.; Wu, Z.; Qiu, Y.K. Two new cytotoxic compounds from a deep-sea Penicillum citreonigrum XT20-134. Mar. Drugs; 2019; 17, 509. [DOI: https://dx.doi.org/10.3390/md17090509] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31470583]
63. Weng, W.Y.; Li, R.D.; Zhang, Y.X.; Pan, X.F.; Jiang, S.C.; Sun, C.C.; Zhang, C.; Lu, X.M. Polyketides isolated from an endophyte Penicillium oxalicum 2021CDF-3 inhibit pancreatic tumor growth. Front. Microbiol.; 2022; 13, 1033823. [DOI: https://dx.doi.org/10.3389/fmicb.2022.1033823] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36225350]
64. Yong, K.; Kaleem, S.; Wu, B.; Zhan, Z.Z. New antiproliferative compounds against glioma cells from the marine-sourced fungus Penicillium sp. ZZ1750. Mar. Drugs; 2021; 19, 483. [DOI: https://dx.doi.org/10.3390/md19090483]
65. Yu, G.; Sun, P.; Aierken, R.; Sun, C.; Zhang, Z.; Che, Q.; Zhang, G.; Zhu, T.; Gu, Q.; Li, M.
66. Huo, R.; Zhang, J.; Niu, S.; Liu, L. New prenylated indole diketopiperazine alkaloids and polyketides from the mangrove-derived fungus Penicillium sp. Front. Mar. Sci.; 2022; 9, 1097594. [DOI: https://dx.doi.org/10.3389/fmars.2022.1097594]
67. Xia, M.W.; Yang, Y.; Xu, R.; Li, C.W.; Cui, C.B. A new polyketide purpurogenic acid: The activated production of polyketides by the diethyl sulphate mutagenesis of marine-derived Penicillium purpurogenum G59. Nat. Prod. Res.; 2018; 33, pp. 89-94. [DOI: https://dx.doi.org/10.1080/14786419.2018.1434644]
68. Zhao, D.L.; Yuan, X.L.; Du, Y.M.; Zhang, Z.F.; Zhang, P. Benzophenone derivatives from an algal-endophytic isolate of Penicillium chrysogenum and their cytotoxicity. Molecules; 2018; 23, 3378. [DOI: https://dx.doi.org/10.3390/molecules23123378]
69. Zheng, C.J.; Liao, H.X.; Mei, R.Q.; Huang, G.L.; Yang, L.J.; Zhou, X.M.; Shao, T.M.; Chen, G.; Wang, C.Y. Two new benzophenones and one new natural amide alkaloid isolated from a mangrove-derived fungus Penicillium citrinum. Nat. Prod. Res.; 2018; 33, pp. 1127-1134. [DOI: https://dx.doi.org/10.1080/14786419.2018.1460832]
70. Cao, G.P.; Xia, J.L.; Zhao, L.Y.; Tang, Z.Z.; Lin, X.; Liu, Y.H.; Gao, C.H.; Liu, K.; Bai, M. Penicixanthene E, a new xanthene isolated from a mangrove-derived fungus Penicillium sp. J. Antibiot.; 2022; 75, pp. 526-529. [DOI: https://dx.doi.org/10.1038/s41429-022-00548-0]
71. Chen, L.; Li, Y.P.; Li, X.X.; Lu, Z.H.; Zheng, Q.H.; Liu, Q.-Y. Isolation of 4,4′-bond secalonic acid D from the marine-derived fungus Penicillium oxalicum with inhibitory property against hepatocellular carcinoma. J. Antibiot.; 2018; 72, pp. 34-44. [DOI: https://dx.doi.org/10.1038/s41429-018-0104-5] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30258223]
72. Dahlem Junior, M.A.; Nguema Edzang, R.W.; Catto, A.L.; Raimundo, J.M. Quinones as an efficient molecular scaffold in the antibacterial/antifungal or antitumoral arsenal. Int. J. Mol. Sci.; 2022; 23, 14108. [DOI: https://dx.doi.org/10.3390/ijms232214108] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36430585]
73. Kaliaperumal, K.; Salendra, L.; Liu, Y.; Ju, Z.; Sahu, S.K.; Elumalai, S.; Subramanian, K.; Alotaibi, N.M.; Alshammari, N.; Saeed, M.
74. Wang, L.; Zhang, X.Y.; Zhang, G.J.; Li, D.H.; Zhang, K.J.; Zhang, X.M.; Zhu, T.J.; Che, Q. Overexpression of global regulator pbrlae a leads to the discovery of new polyketide in fungus Penicillium Brocae HDN-12-143. Front. Chem.; 2020; 8, 270.
75. Wang, H.F.; Mei, W.L.; Gai, C.J.; Dai, H.F.; Wang, P.; Tan, Z.Q. Secondary metabolites of marine-derived fungus Penicillium sp. WP-13. Mycosystema; 2022; 41, pp. 782-791.
76. Pang, X.; Cai, G.; Lin, X.; Salendra, L.; Zhou, X.; Yang, B.; Wang, J.; Wang, J.; Xu, S.; Liu, Y. New alkaloids and polyketides from the marine sponge-derived fungus Penicillium sp. SCSIO41015. Mar. Drugs; 2019; 17, 398. [DOI: https://dx.doi.org/10.3390/md17070398]
77. Li, Q.; Xu, W.; Fan, R.; Zhang, J.; Li, Y.; Wang, X.; Han, S.; Liu, W.; Pan, M.; Cheng, Z. Penithoketone and Penithochromones A-L, polyketides from the deep-sea-derived fungus Penicillium thomii YPGA3. J. Nat. Prod.; 2020; 83, pp. 2679-2685. [DOI: https://dx.doi.org/10.1021/acs.jnatprod.0c00571]
78. Zhang, H.M.; Ju, C.X.; Li, G.; Sun, Y.; Peng, Y.; Li, Y.X.; Peng, X.P.; Lou, H.X. Dimeric 1,4-benzoquinone derivatives with cytotoxic activities from the marine-derived fungus Penicillium sp. L129. Mar. Drugs; 2019; 17, 383. [DOI: https://dx.doi.org/10.3390/md17070383]
79. Chen, Y.; Cai, J.; Xia, Z.; Chen, C.; Liu, Y.; Jayasinghe, L.; Wang, X.; Zhou, X. New bioactive polyketides from the mangrove-derived fungus Penicillium sp. SCSIO 41411. Mar. Drugs; 2024; 22, 384. [DOI: https://dx.doi.org/10.3390/md22090384]
80. Yong, K.; Kaleem, S.; Ma, M.Z.; Lian, X.Y.; Zhang, Z.Z. Antiglioma natural products from the marine-associated fungus Penicillium sp. ZZ1750. Molecules; 2022; 27, 7099. [DOI: https://dx.doi.org/10.3390/molecules27207099]
81. Sova, M.; Saso, L. Design and development of Nrf2 modulators for cancer chemoprevention and therapy: A review. Drug Des. Dev. Ther.; 2018; 12, pp. 3181-3197. [DOI: https://dx.doi.org/10.2147/DDDT.S172612] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30288023]
82. Sharifi-Rad, J.; Seidel, V.; Izabela, M.; Monserrat-Mequida, M.; Sureda, A.; Ormazabal, V.; Zuniga, F.A.; Mangalpady, S.S.; Pezzani, R.; Ydyrys, A.
83. Telkoparan Akillilar, P.; Suzen, S.; Saso, L. Pharmacological applications of Nrf2 Inhibitors as potential antineoplastic Drugs. Int. J. Mol. Sci.; 2019; 20, 2025. [DOI: https://dx.doi.org/10.3390/ijms20082025] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31022969]
84. Subramaniam, S.; Selvaduray, K.R.; Radhakrishnan, A.K. Bioactive compounds: Natural defense against cancer?. Biomolecules; 2019; 9, 758. [DOI: https://dx.doi.org/10.3390/biom9120758]
85. Leshchenko, E.V.; Antonov, A.S.; Borkunov, G.V.; Hauschild, J.; Zhuravleva, O.I.; Khudyakova, Y.V.; Menshov, A.S.; Popov, R.S.; Kim, N.Y.; Graefen, M.
86. Hawas, U.W.; El-Kassem, L.T.A.; Ahmed, E.F.; Alghamdi, R.A. Bioactive sulfonyl metabolites from the red sea endophytic fungus Penicillium aculeatum. Nat. Prod. Res.; 2022; 36, pp. 2713-2721. [DOI: https://dx.doi.org/10.1080/14786419.2021.1917571]
87. Xie, C.L.; Zhang, D.; Lin, T.; He, Z.H.; Yan, Q.X.; Cai, Q.; Zhang, X.K.; Yang, X.W.; Chen, H.F. Antiproliferative sorbicillinoids from the deep-sea-derived Penicillium allii-sativi. Front. Microbiol.; 2020; 11, 636948. [DOI: https://dx.doi.org/10.3389/fmicb.2020.636948]
88. Choi, B.K.; Phan, T.H.T.; Hwang, S.; Oh, D.C.; Kang, J.S.; Lee, H.S.; Ngo, T.D.N.; Tran, T.T.V.; Shin, H.J. Resorcinosides A and B, glycosylated alkylresorcinols from a marine-derived strain of the fungus Penicillium janthinellum. J. Nat. Prod.; 2019; 82, pp. 3186-3190. [DOI: https://dx.doi.org/10.1021/acs.jnatprod.9b00776]
89. Anh, N.M.; Huyen, V.T.T.; Quyen, V.T.; Dao, P.T.; Quynh, D.T.; Huong, D.T.M.; Van Cuong, P.; Dat, T.T.H.; Minh, L.T.H. Antimicrobial and cytotoxic secondary metabolites from a marine-derived fungus Penicillium Citrinum VM6. Curr. Microbiol.; 2023; 81, 32. [DOI: https://dx.doi.org/10.1007/s00284-023-03568-7]
90. Dai, L.T.; Yang, L.; Wang, Z.P.; Guo, J.C.; Ma, Q.Y.; Xie, Q.Y.; Dai, H.F.; Yu, Z.F.; Zhao, Y.X. Persteroid, a new steroid from the marine-derived fungus Penicillium sp. ZYX-Z-143. Nat. Prod. Res.; 2024; pp. 1-8. [DOI: https://dx.doi.org/10.1080/14786419.2024.2394834]
91. Kaleem, S.; Qin, L.; Yi, W.; Lian, X.Y.; Zhang, Z. Bioactive metabolites from the mariana trench sediment-derived fungus Penicillium sp. SY2107. Mar. Drugs; 2020; 18, 258. [DOI: https://dx.doi.org/10.3390/md18050258] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32423167]
92. Zha, X.; Ji, R.; Li, Y.; Cao, R.; Zhou, S. Network pharmacology, molecular docking, and molecular dynamics simulation analysis reveal the molecular mechanism of halociline against gastric cancer. Mol. Divers.; 2024; pp. 1-11. [DOI: https://dx.doi.org/10.1007/s11030-024-10822-y] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/38504075]
93. Jiang, L.L.; Tang, J.X.; Bo, Y.H.; Li, Y.Z.; Feng, T.; Zhu, H.W.; Yu, X.; Zhang, X.X.; Zhang, J.L.; Wang, W. Cytotoxic secondary metabolites isolated from the marine alga-associated fungus Penicillium chrysogenum LD-201810. Mar. Drugs; 2020; 18, 276. [DOI: https://dx.doi.org/10.3390/md18050276] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32456085]
94. Chen, X.H.; Zhou, G.L.; Sun, C.X.; Zhang, X.M.; Zhang, G.J.; Zhu, T.J.; Li, J.; Che, Q.; Li, D.H. Penicacids E-G, three new mycophenolic acid derivatives from the marine-derived fungus Penicillium parvum HDN17-478. Chin. J. Nat. Med.; 2020; 18, pp. 850-854. [DOI: https://dx.doi.org/10.1016/S1875-5364(20)60027-9]
95. Anh, N.M.; Minh, L.T.H.; Linh, N.T.; Dao, P.T.; Quynh, D.T.; Huong, D.T.M.; Van Cuong, P.; Huyen, V.T.T.; Dat, T.T.H. Secondary metabolites from marine fungus Penicillium chrysogenum VH17 and their antimicrobial and cytotoxic potential. Biosci. Biotechnol. Bioch.; 2024; 88, pp. 1254-1260. [DOI: https://dx.doi.org/10.1093/bbb/zbae113]
96. Wang, Y.R.; Dong, Y.L.; Li, X.M.; Shi, X.S.; Li, H.L.; Meng, L.H.; Xu, R.; Wang, B.G. Curvularin derivatives from the marine mangrove derived fungus Penicillium sumatrense MA-325. Phytochemistry; 2024; 220, 114000. [DOI: https://dx.doi.org/10.1016/j.phytochem.2024.114000]
97. Wang, J.J.; Li, K.L.; Luo, X.W.; Wu, Z.Y.; Gu, T.W.; Liao, S.R.; Lin, X.P.; Yang, B.; Liu, Y.H.; Zhou, X.F. Sorbicillfurans A and B, two novel sorbicillinoid adducts from the fungus Penicillium citrinum SCSIO41402. Org. Biomol. Chem.; 2019; 17, pp. 8721-8725. [DOI: https://dx.doi.org/10.1039/C9OB01595G]
98. Buachan, P.; Namsa Aid, M.; Sung, H.K.; Peng, C.; Sweeney, G.; Tanechpongtamb, W. Inhibitory effects of terrein on lung cancer cell metastasis and angiogenesis. Oncol. Rep.; 2021; 45, 94. [DOI: https://dx.doi.org/10.3892/or.2021.8045]
99. Mondal, A.; Gandhi, A.; Fimognari, C.; Atanasov, A.G.; Bishayee, A. Alkaloids for cancer prevention and therapy: Current progress and future perspectives. Eur. J. Pharmacol.; 2019; 858, 172472. [DOI: https://dx.doi.org/10.1016/j.ejphar.2019.172472]
100. Scherlach, K.; Boettger, D.; Remme, N.; Hertweck, C. The chemistry and biology of cytochalasans. Nat. Prod. Rep.; 2010; 27, pp. 869-886. [DOI: https://dx.doi.org/10.1039/b903913a]
101. Cheng, Z.; Li, Y.; Xu, W.; Liu, W.; Liu, L.; Zhu, D.; Kang, Y.; Luo, Z.; Li, Q. Three new cyclopiane-type diterpenes from a deep-sea derived fungus Penicillium sp. YPGA11 and their effects against human esophageal carcinoma cells. Bioorganic Chem.; 2019; 91, 103129. [DOI: https://dx.doi.org/10.1016/j.bioorg.2019.103129] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31374522]
102. Niu, S.; Wang, N.; Xie, C.L.; Fan, Z.; Luo, Z.; Chen, H.F.; Yang, X.W. Roquefortine J, a novel roquefortine alkaloid, from the deep-sea-derived fungus Penicillium granulatum MCCC 3A00475. J. Antibiot.; 2018; 71, pp. 658-661. [DOI: https://dx.doi.org/10.1038/s41429-018-0046-y] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/29618769]
103. Wibowo, J.T.; Ahmadi, P.; Rahmawati, S.I.; Bayu, A.; Putra, M.Y.; Kijjoa, A. Marine-derived indole alkaloids and their biological and pharmacological activities. Mar. Drugs; 2021; 20, 3. [DOI: https://dx.doi.org/10.3390/md20010003] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35049859]
104. Dadashpour, S.; Emami, S. Indole in the target-based design of anticancer agents: A versatile scaffold with diverse mechanisms. Eur. J. Med. Chem.; 2018; 150, pp. 9-29. [DOI: https://dx.doi.org/10.1016/j.ejmech.2018.02.065]
105. Dyshlovoy, S.A.; Zhuravleva, O.I.; Hauschild, J.; Busenbender, T.; Pelageev, D.N.; Yurchenko, A.N.; Khudyakova, Y.V.; Antonov, A.S.; Graefen, M.; Bokemeyer, C.
106. Li, S.; Ma, Y.; Wang, L.; Lan, D.; Fu, L.; Wu, B. Two new alkaloids from the marine-derived fungus Penicillium sp. LSH-3-1. Chem. Biodivers.; 2022; 19, e202200310. [DOI: https://dx.doi.org/10.1002/cbdv.202200310]
107. Liu, L.; Xu, W.; Li, S.; Chen, M.; Cheng, Y.; Yuan, W.; Cheng, Z.; Li, Q. Penicindopene A, a new indole diterpene from the deep-sea fungus Penicillium sp. YPCMAC1. Nat. Prod. Res.; 2019; 33, pp. 2988-2994. [DOI: https://dx.doi.org/10.1080/14786419.2018.1514402]
108. Kong, F.D.; Fan, P.; Zhou, L.M.; Ma, Q.Y.; Xie, Q.Y.; Zheng, H.Z.; Zheng, Z.H.; Zhang, R.S.; Yuan, J.Z.; Dai, H.F.
109. Zhang, Y.H.; Wang, C.Y.; Geng, C.; Zhang, X.W.; Zhu, H.J.; Shao, C.L.; Cao, F. Discovery of bioactive indole-diketopiperazines from the marine-derived fungus Penicillium brasilianum aided by genomic information. Mar. Drugs; 2019; 17, 514. [DOI: https://dx.doi.org/10.3390/md17090514]
110. Song, W.; Ji, L.; Zhang, Y.; Cao, L. New cytotoxic indole derivatives with anti-FADU potential produced by the endophytic fungus Penicillium oxalicum 2021CDF-3 through the OSMAC strategy. Front. Microbiol.; 2024; 15, 1400803. [DOI: https://dx.doi.org/10.3389/fmicb.2024.1400803]
111. Wang, N.; Dong, Y.; Yang, Y.; Xu, R.; Li, C.W.; Cui, C.B. Penicimutanin C, a new alkaloidal compound, Isolated from a neomycin-resistant mutant 3-f-31of Penicillium purpurogenum G59. Chem. Biodivers.; 2020; 17, e2000241. [DOI: https://dx.doi.org/10.1002/cbdv.202000241] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32385896]
112. He, Z.H.; Wu, J.; Xu, L.; Hu, M.Y.; Xie, M.M.; Hao, Y.J.; Li, S.J.; Shao, Z.Z.; Yang, X.W. Chemical constituents of the deep-sea-derived Penicillium solitum. Mar. Drugs; 2021; 19, 580. [DOI: https://dx.doi.org/10.3390/md19100580] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34677479]
113. Ding, Y.; Jiang, Y.; Xu, S.; Xin, X.; An, F. Perpyrrospirone A, an unprecedented hirsutellone peroxide from the marine-derived Penicillium citrinum. Chinese. Chem. Lett.; 2023; 34, 076. [DOI: https://dx.doi.org/10.1016/j.cclet.2022.05.076]
114. Song, T.; Tang, M.; Ge, H.; Chen, M.; Lian, X.; Zhang, Z. Novel bioactive Penicipyrroether A and Pyrrospirone J from the marine-derived Penicillium sp. ZZ380. Mar. Drugs; 2019; 17, 292. [DOI: https://dx.doi.org/10.3390/md17050292] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31096582]
115. Song, T.; Chen, M.; Chai, W.; Zhang, Z.; Lian, X.Y. New bioactive pyrrospirones C–I from a marine-derived fungus Penicillium sp. ZZ380. Tetrahedron; 2018; 74, pp. 884-891. [DOI: https://dx.doi.org/10.1016/j.tet.2018.01.015]
116. Guo, X.C.; Zhang, Y.H.; Gao, W.B.; Pan, L.; Zhu, H.J.; Cao, F. Absolute configurations and chitinase inhibitions of quinazoline-containing diketopiperazines from the marine-derived fungus Penicillium polonicum. Mar. Drugs; 2020; 18, 479. [DOI: https://dx.doi.org/10.3390/md18090479]
117. Gu, Y.; Ding, P.; Liang, Z.; Song, Y.; Liu, Y.; Chen, G.; Li, J.L. Activated production of silent metabolites from marine-derived fungus Penicillium citrinum. Fitoterapia; 2018; 127, pp. 207-211. [DOI: https://dx.doi.org/10.1016/j.fitote.2018.02.012]
118. Youssef, D.; Alahdal, A. Cytotoxic and antimicrobial compounds from the marine-derived fungus, Penicillium Species. Molecules; 2018; 23, 394. [DOI: https://dx.doi.org/10.3390/molecules23020394]
119. Cai, J.; Wang, X.; Yang, Z.; Tan, Y.; Peng, B.; Liu, Y.; Zhou, X. Thiodiketopiperazines and alkane derivatives produced by the mangrove sediment-derived fungus Penicillium ludwigii SCSIO 41408. Front. Microbiol.; 2022; 13, 857041. [DOI: https://dx.doi.org/10.3389/fmicb.2022.857041]
120. Sun, L.X.; Wang, H.N.; Yan, M.C.; Sai, C.M.; Zhang, Z. Research advances of bioactive sesquiterpenoids isolated from marine-derived Aspergillus sp. Molecules; 2022; 27, 7376. [DOI: https://dx.doi.org/10.3390/molecules27217376]
121. Gershenzon, J.; Dudareva, N. The function of terpene natural products in the natural world. Nat. Chem. Biol.; 2007; 3, pp. 408-414. [DOI: https://dx.doi.org/10.1038/nchembio.2007.5] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17576428]
122. Chopra, B.; Dhingra, A.K.; Dhar, K.L.; Nepali, K. Emerging role of terpenoids for the treatment of cancer: A review. Mini Rev. Med. Chem.; 2021; 21, pp. 2300-2336. [DOI: https://dx.doi.org/10.2174/1389557521666210112143024] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33438537]
123. Jin, Y.; Tian, S.; Xue, J. Isolation and structure determination of a new bisabolane-type sesquiterpenoid with cytotoxicity from Penicillium oxalicum MZY-202312-521. Nat. Prod. Res.; 2024; pp. 1-5. [DOI: https://dx.doi.org/10.1080/14786419.2024.2356651] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/38824430]
124. Ma, M.Z.; Ge, H.J.; Yi, W.W.; Wu, B.; Zhang, Z.Z. Bioactive drimane sesquiterpenoids and isocoumarins from the marine-derived fungus Penicillium minioluteum ZZ1657. Tetrahedron Lett.; 2020; 61, 151504. [DOI: https://dx.doi.org/10.1016/j.tetlet.2019.151504]
125. Leshchenko, E.V.; Chingizova, E.A.; Antonov, A.S.; Shlyk, N.P.; Borkunov, G.V.; Berdyshev, D.V.; Chausova, V.E.; Kirichuk, N.N.; Khudyakova, Y.V.; Chingizov, A.R.
126. Zhang, J.; Liu, D.; Fan, A.; Huang, J.; Lin, W. Eremophilane-type sesquiterpenes from a marine-derived fungus Penicillium Copticola with antitumor and neuroprotective activities. Mar. Drugs; 2022; 20, 712. [DOI: https://dx.doi.org/10.3390/md20110712]
127. Leshchenko, E.V.; Antonov, A.S.; Dyshlovoy, S.A.; Berdyshev, D.V.; Hauschild, J.; Zhuravleva, O.I.; Borkunov, G.V.; Menshov, A.S.; Kirichuk, N.N.; Popov, R.S.
128. Cheng, X.; Liang, X.; Zheng, Z.H.; Zhang, X.X.; Lu, X.H.; Yao, F.H.; Qi, S.H. Penicimeroterpenoids A-C, meroterpenoids with rearrangement skeletons from the marine-derived fungus Penicillium sp. SCSIO 41512. Org. Lett.; 2020; 22, pp. 6330-6333. [DOI: https://dx.doi.org/10.1021/acs.orglett.0c02160]
129. Ren, J.; Huo, R.; Liu, G.; Liu, L. New andrastin-type meroterpenoids from the marine-derived fungus Penicillium sp. Mar. Drugs; 2021; 19, 189. [DOI: https://dx.doi.org/10.3390/md19040189]
130. Yang, Y.; Han, X.; Jiang, C.; Chen, Y.; Tang, X.; Li, G.Q. Penisimplinoids A-K, highly oxygenated andrastin-type meroterpenoids with diverse activities from the marine-derived fungus Penicillium simplicissimum. Bioorganic Chem.; 2024; 153, 107897. [DOI: https://dx.doi.org/10.1016/j.bioorg.2024.107897]
131. Xie, C.L.; Xia, J.M.; Lin, T.; Lin, Y.J.; Lin, Y.K.; Xia, M.L.; Chen, H.F.; Luo, Z.H.; Shao, Z.Z.; Yang, X.W. Andrastone A from the deep-sea-derived fungus Penicillium allii-sativi acts as an inducer of caspase and RXRalpha-dependent apoptosis. Front. Chem.; 2019; 7, 692. [DOI: https://dx.doi.org/10.3389/fchem.2019.00692] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31737594]
132. Cheng, Z.; Liu, W.; Fan, R.; Han, S.; Li, Y.; Cui, X.; Zhang, J.; Wu, Y.; Lv, X.; Zhang, Y.
133. Long, J.Y.; Wang, J.F.; Liao, S.R.; Lin, X.P.; Zhou, X.F.; Li, Y.Q.; Yang, B.; Liu, Y.H. Four new steroids from the marine soft coral-derived fungus Penicillium sp. SCSIO41201. Chin. J. Nat. Med.; 2020; 18, pp. 250-255. [DOI: https://dx.doi.org/10.1016/S1875-5364(20)30030-3] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32402400]
134. Yang, B.Y.; Sun, W.G.; Wang, J.P.; Lin, S.; Li, X.N.; Zhu, H.C.; Luo, Z.W.; Xue, Y.B.; Hu, Z.X.; Zhang, Y.H. A new breviane spiroditerpenoid from the marine-derived fungus Penicillium sp. TJ403-1. Mar. Drugs; 2018; 16, 110. [DOI: https://dx.doi.org/10.3390/md16040110]
135. Sun, X.; Wang, W.; Chen, J.; Cai, X.; Yang, J.; Yang, Y.; Yan, H.; Cheng, X.; Ye, J.; Lu, W.
136. Tang, P.; Liu, D.; Wu, Z.; Cui, H.; Zhang, R.; Kuang, Z. Inhibitory effects and mechanism of the natural compound diaporthein b extracted from marine-derived fungi on colon cancer cells. Molecules; 2022; 27, 2944. [DOI: https://dx.doi.org/10.3390/molecules27092944]
137. Hoang, C.K.; Le, C.H.; Nguyen, D.T.; Tran, H.T.N.; Luu, C.V.; Le, H.M.; Tran, H.T.H. Steroid components of marine-derived fungal strain Penicillium levitum N33.2 and their biological activities. Mycobiology; 2023; 51, pp. 246-255. [DOI: https://dx.doi.org/10.1080/12298093.2023.2248717]
138. He, Z.H.; Xie, C.L.; Hao, Y.J.; Xu, L.; Wang, C.F.; Hu, M.Y.; Li, S.J.; Zhong, T.H.; Yang, X.W. Solitumergosterol A, a unique 6/6/6/6/5 steroid from the deep-sea-derived Penicillium solitum MCCC 3A00215. Org. Biomol. Chem.; 2021; 19, pp. 9369-9372. [DOI: https://dx.doi.org/10.1039/D1OB01392K]
139. Xie, C.L.; Zhang, D.; Xia, J.M.; Hu, C.C.; Lin, T.; Lin, Y.K.; Wang, G.H.; Tian, W.J.; Li, Z.P.; Zhang, X.K.
140. Shi, Z.; Zhang, M.; Fan, H.; Chen, Y.; Dong, S.; Zhou, F.; Wang, B.; Liu, J.; Jin, J.; Luo, Y.
141. Sun, M.H.; Li, X.H.; Xu, Y.; Xu, Y.; Pan, Z.N.; Sun, S.C. Citrinin exposure disrupts organelle distribution and functions in mouse oocytes. Environ. Res.; 2020; 185, 109476. [DOI: https://dx.doi.org/10.1016/j.envres.2020.109476] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32278162]
142. Propper, D.J.; Balkwill, F.R. Harnessing cytokines and chemokines for cancer therapy. Nat. Rev. Clin. Oncol.; 2022; 19, pp. 237-253. [DOI: https://dx.doi.org/10.1038/s41571-021-00588-9] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34997230]
143. Alfaro, C.; Sanmamed, M.F.; Rodríguez-Ruiz, M.E.; Teijeira, Á.; Oñate, C.; González, Á.; Ponz, M.; Schalper, K.A.; Pérez-Gracia, J.L.; Melero, I. Interleukin-8 in cancer pathogenesis, treatment and follow-up. Cancer Treat. Rev.; 2017; 60, pp. 24-31. [DOI: https://dx.doi.org/10.1016/j.ctrv.2017.08.004] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28866366]
144. Dumitrescu, T.; Uscatu, C.D.; Alexandru, D.O.; MEŞINĂ, C. Correlations between intratumoral microvessel density and histopathological type or neoadjuvant radiotherapy for rectal carcinoma. Curr. Health Sci. J.; 2015; 41, pp. 152-157.
145. Couchie, D.; Vaisman, B.; Abderrazak, A.; Mahmood, D.F.D.; Hamza, M.M.; Canesi, F.; Diderot, V.; Hadri, K.E.; Nègre-Salvayre, A.; Page, A.L.
146. Su, C.M.; Wang, I.C.; Liu, S.C.; Sun, Y.; Jin, L.; Wang, S.W.; Lee, H.P.; Tseng, W.P.; Tang, C.H. Hypoxia induced mitogenic factor (HIMF) triggers angiogenesis by increasing interleukin-18 production in myoblasts. Sci. Rep.; 2017; 7, 7393. [DOI: https://dx.doi.org/10.1038/s41598-017-07952-9]
147. Kobori, T.; Hamasaki, S.; Kitaura, A.; Yamazaki, Y.; Nishinaka, T.; Niwa, A.; Nakao, S.; Wake, H.; Mori, S.; Yoshino, T.
148. Sallam, A.A.; Houssen, W.E.; Gissendanner, C.R.; Orabi, K.Y.; Foudaha, A.I.; Sayed, K.A.E. Bioguided discovery and pharmacophore modeling of the mycotoxic indole diterpene alkaloids penitrems as breast cancer proliferation, migration, and invasion inhibitors. Med. Chem. Commun.; 2013; 4, pp. 1360-1369. [DOI: https://dx.doi.org/10.1039/c3md00198a]
149. Goda, A.A.; Siddique, A.B.; Mohyeldin, M.; Ayoub, N.M.; El Sayed, K.A. The maxi-k (BK) channel antagonist penitrem a as a novel breast cancer-targeted therapeutic. Mar. Drugs; 2018; 16, 157. [DOI: https://dx.doi.org/10.3390/md16050157]
150. Schlange, T.; Matsuda, Y.; Lienhard, S.; Huber, A.; Hynes, N.E. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res.; 2007; 9, R63. [DOI: https://dx.doi.org/10.1186/bcr1769]
151. Mei, L.; Lu, W.; Lin, C.; Roberts, M.J.; Waud, W.R.; Piazza, G.A.; Li, Y. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway. PLoS ONE; 2011; 6, e29290.
152. Sallam, A.A.; Ayoub, N.M.; Foudah, A.I.; Gissendanner, C.R.; Meyer, S.A.; El Sayed, K.A. Indole diterpene alkaloids as novel inhibitors of the Wnt/β-catenin pathway in breast cancer cells. Eur. J. Med. Chem.; 2013; 70, pp. 594-606. [DOI: https://dx.doi.org/10.1016/j.ejmech.2013.09.045] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24211635]
153. Yamada, K.; Hori, Y.; Inoue, S.; Yamamoto, Y.; Iso, K.; Kamiyama, H.; Yamaguchi, A.; Kimura, T.; Uesugi, M.; Ito, J.
154. Zhu, M.L.; Zhang, X.M.; Feng, H.M.; Dai, J.J.; Li, J.; Che, Q.; Gu, Q.Q.; Zhu, T.J.; Li, D.H. Penicisulfuranols A-F, alkaloids from the mangrove endophytic fungus Penicillium janthinellum HDN13-309. J. Nat. Prod.; 2017; 80, pp. 71-75. [DOI: https://dx.doi.org/10.1021/acs.jnatprod.6b00483]
155. Hoy, S.M. Pimitespib: First approval. Drugs; 2022; 82, pp. 1413-1418. [DOI: https://dx.doi.org/10.1007/s40265-022-01764-6]
156. Dai, J.; Chen, A.; Zhu, M.; Qi, X.; Tang, W.; Liu, M.; Li, D.; Gu, Q.; Li, J. Penicisulfuranol A, a novel c-terminal inhibitor disrupting molecular chaperone function of Hsp90 independent of ATP binding domain. Biochem. Pharmacol.; 2019; 163, pp. 404-415. [DOI: https://dx.doi.org/10.1016/j.bcp.2019.03.012]
157. Gayler, K.M.; Lambert, K.M.; Wood, J.L. Synthetic studies towards the penicisulfuranols: Synthesis of an advanced spirocyclic diketopiperazine intermediate. Tetrahedron; 2019; 75, pp. 3154-3159. [DOI: https://dx.doi.org/10.1016/j.tet.2019.01.032]
158. Steyn, P.S. The isolation, structure and absolute configuration of secalonic acid D, the toxic metabolite of Penicillium oxalicum. Tetrahedron; 1970; 26, pp. 51-57. [DOI: https://dx.doi.org/10.1016/0040-4020(70)85006-2]
159. Ren, H.; Tian, L.; Gu, Q.; Zhu, W. Secalonic acid D; A cytotoxic constituent from marine lichen-derived fungus gliocladium sp. T31. Arch. Pharm. Res.; 2006; 29, pp. 59-63. [DOI: https://dx.doi.org/10.1007/BF02977469]
160. Zhang, J.Y.; Tao, L.Y.; Liang, Y.J.; Yan, Y.Y.; Dai, C.l.; Xia, X.K.; She, Z.G.; Lin, Y.C.; Fu, L.W. Secalonic acid D induced leukemia cell apoptosis and cell cycle arrest of G1 with involvement of GSK-3β/β-catenin/c-Myc pathway. Cell Cycle; 2009; 8, pp. 2444-2450. [DOI: https://dx.doi.org/10.4161/cc.8.15.9170]
161. Hong, R. Secalonic acid D as a novel DNA topoisomerase I inhibitor from marine lichen-derived fungus Gliocladium sp. T31. Pharm. Biol.; 2011; 49, pp. 796-799. [DOI: https://dx.doi.org/10.3109/13880209.2010.548817] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21495809]
162. Chen, L.; Cheng, M.M.; Li, Y.P.; Lin, S.F.; Zheng, Q.H.; Liu, Q.Y. 4,4′-bond secalonic acid D targets SP cells and inhibits metastasis in hepatocellular carcinoma. Mol. Med. Rep.; 2020; 21, pp. 2624-2632. [DOI: https://dx.doi.org/10.3892/mmr.2020.11055] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32323850]
163. Hu, M.; Li, W.; Zhang, Y.; Liang, C.; Tan, J.; Wang, Y. Venetoclax in adult acute myeloid leukemia. Biomed. Pharmacother.; 2023; 168, 115820. [DOI: https://dx.doi.org/10.1016/j.biopha.2023.115820] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/37925935]
164. Liu, W.; Cui, X.; Zhong, Y.; Ma, R.; Liu, B.; Xia, Y. Phenolic metabolites as therapeutic in inflammation and neoplasms: Molecular pathways explaining their efficacy. Pharmacol. Res.; 2023; 193, 106812. [DOI: https://dx.doi.org/10.1016/j.phrs.2023.106812]
165. Vitaku, E.; Smith, D.T.; Njardarson, J.T. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals. J. Med. Chem.; 2014; 57, pp. 10257-10274. [DOI: https://dx.doi.org/10.1021/jm501100b]
166. Ansari, M.F.; Khan, H.Y.; Tabassum, S.; Arjmand, F. Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects. Pharmacol. Therapeut.; 2023; 241, 108335. [DOI: https://dx.doi.org/10.1016/j.pharmthera.2022.108335]
167. Pennington, L.D.; Moustakas, D.T. The necessary nitrogen atom: A versatile high-impact design element for multiparameter optimization. J. Med. Chem.; 2017; 60, pp. 3552-3579. [DOI: https://dx.doi.org/10.1021/acs.jmedchem.6b01807]
168. Babaei, G.; Aliarab, A.; Abroon, S.; Rasmi, Y.; Aziz, S.G.G. Application of sesquiterpene lactone: A new promising way for cancer therapy based on anticancer activity. Biomed. Pharmacother.; 2018; 106, pp. 239-246. [DOI: https://dx.doi.org/10.1016/j.biopha.2018.06.131]
169. Zolottsev, V.A.; Latysheva, A.S.; Pokrovsky, V.S.; Khan, I.I.; Misharin, A.Y. Promising applications of steroid conjugates for cancer research and treatment. Eur. J. Med. Chem.; 2021; 210, 113089. [DOI: https://dx.doi.org/10.1016/j.ejmech.2020.113089]
170. Chinnappan, R.S.; Kandasamy, K.; Sekar, A. A review on marine based nanoparticles and their potential applications. Afr. J. Biotechnol.; 2015; 14, pp. 1525-1532. [DOI: https://dx.doi.org/10.5897/AJB2015.14527]
171. Colone, M.; Calcabrini, A.; Stringaro, A. Drug delivery systems of natural products in oncology. Molecules; 2020; 25, 4560. [DOI: https://dx.doi.org/10.3390/molecules25194560] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33036240]
172. Criscitiello, C.; Morganti, S.; Curigliano, G. Antibody–drug conjugates in solid tumors: A look into novel targets. J. Hematol. Oncol.; 2021; 14, 20. [DOI: https://dx.doi.org/10.1186/s13045-021-01035-z]
173. Csermely, P.; Agoston, V.; Pongor, S. The efficiency of multi-target drugs: The network approach might help drug design. Trends Pharmacol. Sci.; 2005; 26, pp. 178-182. [DOI: https://dx.doi.org/10.1016/j.tips.2005.02.007] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15808341]
174. Su, F.; Song, Q.; Zhang, C.; Xu, X.; Li, M.; Yao, D.; Wu, L.; Qu, X.; Guan, H.; Yu, G.
175. Song, Q.; Xu, Y.; Zhang, M.; Wu, L.; Liu, S.; Lv, Y.; Hu, T.; Zhao, J.; Zhang, X.; Xu, X.
176. Pautier, P.; Italiano, A.; Piperno-Neumann, S.; Chevreau, C.; Penel, N.; Firmin, N.; Boudou-Rouquette, P.; Bertucci, F.; Balleyguier, C.; Lebrun-Ly, V.
177. Pautier, P.; Italiano, A.; Piperno-Neumann, S.; Chevreau, C.; Penel, N.; Firmin, N.; Boudou-Rouquette, P.; Bertucci, F.; Lebrun-Ly, V.; Ray-Coquard, I.
178. Atmaca, H.; Oğuz, F.; Ilhan, S. Trabectedin (ET-743) in prostate cancer: Endoplasmic reticulum stress-induced apoptotic effect. Andrologia; 2022; 54, e14599. [DOI: https://dx.doi.org/10.1111/and.14599]
179. Liang, X.; Luo, D.; Luesch, H. Advances in exploring the therapeutic potential of marine natural products. Pharmacol. Res.; 2019; 147, 104373. [DOI: https://dx.doi.org/10.1016/j.phrs.2019.104373]
180. Wang, Y.X.; Wang, F.; Liu, W.X.; Geng, Y.F.; Shi, Y.H.; Tian, Y.; Zhang, B.; Luo, Y.; Sun, X.B. New drug discovery and development from natural products: Advances and strategies. Pharmacol. Therapeut.; 2024; 264, 108752. [DOI: https://dx.doi.org/10.1016/j.pharmthera.2024.108752]
181. Gangwal, A.; Ansari, A.; Ahmad, I.; Azad, A.K.; Wan Sulaiman, W.M.A. Current strategies to address data scarcity in artificial intelligence-based drug discovery: A comprehensive review. Comput. Biol. Med.; 2024; 179, 108734. [DOI: https://dx.doi.org/10.1016/j.compbiomed.2024.108734] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/38964243]
182. Lovitt, C.J.; Shelper, T.B.; Avery, V.M. Cancer drug discovery: Recent innovative approaches to tumor modeling. Expert Opin. Drug Dis.; 2016; 11, pp. 885-894. [DOI: https://dx.doi.org/10.1080/17460441.2016.1214562] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27454169]
183. Velasquez, J.E.; Van der Donk, W.A. Genome mining for ribosomally synthesized natural products. Curr. Opin. Chem. Biol.; 2011; 15, pp. 11-21. [DOI: https://dx.doi.org/10.1016/j.cbpa.2010.10.027] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21095156]
184. Chu, L.; Huang, J.; Muhammad, M.; Deng, Z.; Gao, J. Genome mining as a biotechnological tool for the discovery of novel marine natural products. Crit. Rev. Biotechnol.; 2020; 40, pp. 571-589. [DOI: https://dx.doi.org/10.1080/07388551.2020.1751056]
185. Imhoff, J.F.; Labes, A.; Wiese, J. Bio-mining the microbial treasures of the ocean: New natural products. Biotechnol. Adv.; 2011; 29, pp. 468-482. [DOI: https://dx.doi.org/10.1016/j.biotechadv.2011.03.001]
186. Caudal, F.; Tapissier-Bontemps, N.; Edrada-Ebel, R.A. Impact of co-culture on the metabolism of marine microorganisms. Mar. Drugs; 2022; 20, 153. [DOI: https://dx.doi.org/10.3390/md20020153]
187. Pinedo-Rivilla, C.; Aleu, J.; Duran-Patron, R. Cryptic metabolites from marine-derived microorganisms using OSMAC and epigenetic approaches. Mar. Drugs; 2022; 20, 84. [DOI: https://dx.doi.org/10.3390/md20020084]
188. Manouchehri, N.; Bouguila, N. Human activity recognition with an HMM-based generative model. Sensors; 2023; 23, 1390. [DOI: https://dx.doi.org/10.3390/s23031390]
189. Sukmarini, L. Marine bacterial ribosomal peptides: Recent genomics- and synthetic biology-based discoveries and biosynthetic studies. Mar. Drugs; 2022; 20, 544. [DOI: https://dx.doi.org/10.3390/md20090544]
190. Wang, S.W.; Gao, C.; Zheng, Y.M.; Yi, L.; Lu, J.C.; Huang, X.Y.; Cai, J.B.; Zhang, P.F.; Cui, Y.H.; Ke, A.W. Current applications and future perspective of CRISPR/Cas9 gene editing in cancer. Mol. Cancer; 2022; 21, 57. [DOI: https://dx.doi.org/10.1186/s12943-022-01518-8]
191. Tian, J.; Yang, G.; Gu, Y.; Sun, X.; Lu, Y.; Jiang, W. Developing an endogenous quorum-sensing based CRISPRi circuit for autonomous and tunable dynamic regulation of multiple targets in streptomyces. Nucleic Acids Res.; 2020; 48, pp. 8188-8202. [DOI: https://dx.doi.org/10.1093/nar/gkaa602] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32672817]
192. Zhai, X.; Yao, L.; Zhou, Y.J. Construction of microbial chassis for terpenoid discovery. Syn. Syst. Biotechno.; 2022; 7, pp. 1181-1182. [DOI: https://dx.doi.org/10.1016/j.synbio.2022.09.002] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/36262714]
193. Timmermans, M.L.; Paudel, Y.P.; Ross, A.C. Investigating the biosynthesis of natural products from marine proteobacteria: A survey of molecules and strategies. Mar. Drugs; 2017; 15, 235. [DOI: https://dx.doi.org/10.3390/md15080235] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28762997]
194. Xie, Y.; Chen, J.; Wang, B.; Chen, T.; Chen, J.; Zhang, Y.; Liu, X.; Chen, Q. Activation and enhancement of caerulomycin a biosynthesis in marine-derived Actinoalloteichus sp. AHMU CJ021 by combinatorial genome mining strategies. Microb. Cell Fact.; 2020; 19, 159. [DOI: https://dx.doi.org/10.1186/s12934-020-01418-w]
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Details
1 School of Pharmacy, Binzhou Medical University, 346 Guanhai Road, Yantai 264003, China; [email protected], School of Pharmacy, Jining Medical University, 669 Xueyuan Road, Rizhao 276800, China; [email protected] (H.W.); [email protected] (C.S.); [email protected] (Y.W.)
2 School of Pharmacy, Jining Medical University, 669 Xueyuan Road, Rizhao 276800, China; [email protected] (H.W.); [email protected] (C.S.); [email protected] (Y.W.)
3 Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China